LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Preimplantation Genetic Testing for Aneuploidy Kits market with holistic insights into vital factors and aspects that impact future market growth. The global Preimplantation Genetic Testing for Aneuploidy Kits market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Preimplantation Genetic Testing for Aneuploidy Kits market and its critical dynamics, the research study provides detailed qualitative and quantitative analysis. Furthermore, readers are offered with complete and thorough research on different regions and segments of the global Preimplantation Genetic Testing for Aneuploidy Kits market. Almost all industry-specific, microeconomic, and macroeconomic factors influencing the global market growth have been analyzed in the report.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/4374433/global-preimplantation-genetic-testing-for-aneuploidy-kits-market

With an exhaustive analysis of the competitive landscape, the authors of the Preimplantation Genetic Testing for Aneuploidy Kits market report have made a brilliant attempt to explore key developments, pricing and business tactics, and future plans of leading companies. Besides the Preimplantation Genetic Testing for Aneuploidy Kits market performance of players in terms of revenue and sales, the analysts shed light on their production, areas served, gross margin, and other important factors. In addition, the Preimplantation Genetic Testing for Aneuploidy Kits report helps players to gain an upper hand in the market competition as it deeply analyzes the market positioning, market growth, and product portfolio of their competitors.

Key Players Mentioned in the Global Preimplantation Genetic Testing for Aneuploidy Kits Market Research Report: PerkinElmerIlluminaThermo Fisher ScientificBASECAREPeking Jabrehoo Med Tech

Global Preimplantation Genetic Testing for Aneuploidy Kits Market Segmentation by Product: Reversible End Termination SequencingIron Semiconductor Sequencing

Global Preimplantation Genetic Testing for Aneuploidy Kits Market Segmentation by Application: Public HospitalPrivate Hospital

The report is the best compilation of different types of segmental analysis of the global Preimplantation Genetic Testing for Aneuploidy Kits market conducted from different angles. The pragmatic approach taken by analysts to study various market segments and the top-down and bottom-up approaches adopted to forecast their market sizes make Preimplantation Genetic Testing for Aneuploidy Kits research study unique and accurate. For validation and revalidation of market figures and other findings, reliable primary sources such as technology and innovation directors, MDs, VPs, CEOs, and supply-side and demand-side industry experts were consulted. Secondary sources such as Bloomberg, databases, white papers, press releases, and company reports were used to collect market information and data.

This research study can be used by all participants of the global Preimplantation Genetic Testing for Aneuploidy Kits market as it covers every major and minor aspect of the current and future market competition. Even for stakeholders, it can prove highly beneficial, considering the range of studies offered along with detailed analysis of growth strategies that players are expected to adopt in the coming years. New entrants or players looking to make a foray into the global Preimplantation Genetic Testing for Aneuploidy Kits market can gather useful information and effective advice from the report. On the other hand, established companies can use the Preimplantation Genetic Testing for Aneuploidy Kits report to stay updated about current and future market scenarios and plan out their future business moves.

Reasons to Procure this Report:

(A) The research would help top administration/policymakers/professionals/product advancements/sales managers and stakeholders in this market in the following ways.

(B) The report provides Preimplantation Genetic Testing for Aneuploidy Kits market revenues at the worldwide, regional, and country-level with a complete analysis to 2028 permitting companies to analyze their market share and analyze projections, and find new markets to aim.

(C) The research includes the Preimplantation Genetic Testing for Aneuploidy Kits market split by different types, applications, technologies, and end-uses. This segmentation helps leaders plan their products and finances based on the upcoming development rates of each segment.

(D) Preimplantation Genetic Testing for Aneuploidy Kits market analysis benefits investors by knowing the scope and position of the market giving them information on key drivers, challenges, restraints, and expansion chances of the market and moderate threats.

(E) This report would help to understand competition better with a detailed analysis and key strategies of their competitors and plan their position in the business.

(F) The study helps evaluate Preimplantation Genetic Testing for Aneuploidy Kits business predictions by region, key countries, and top companies information to channel their investments.

Key Questions Answered in the Report Include:

(1) This report gives all the information about the industry analysis, revenue, and overview, of this market.

(2) What will be the rate of increase in market size and growth rate by the end of the forecast period?

(3) What are the major global Preimplantation Genetic Testing for Aneuploidy Kits market trends influencing the development of the market?

(4) What are the vital results of SWOT analysis of the major players operating in the Preimplantation Genetic Testing for Aneuploidy Kits market?

(5) What are the potential growth opportunities and threats faced by Major competitors in the market?

(6) What are the market opportunities and threats faced by vendors in the Global Preimplantation Genetic Testing for Aneuploidy Kits market?

Request for customization in Report: https://www.qyresearch.com/customize-request/form/4374433/global-preimplantation-genetic-testing-for-aneuploidy-kits-market

Table of Content

1 Preimplantation Genetic Testing for Aneuploidy Kits Market Overview1.1 Preimplantation Genetic Testing for Aneuploidy Kits Product Overview1.2 Preimplantation Genetic Testing for Aneuploidy Kits Market Segment by Type1.2.1 Reversible End Termination Sequencing1.2.2 Iron Semiconductor Sequencing1.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Market Size by Type1.3.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Market Size Overview by Type (2017-2028)1.3.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Historic Market Size Review by Type (2017-2022)1.3.2.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown in Volume by Type (2017-2022)1.3.2.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown in Value by Type (2017-2022)1.3.2.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Average Selling Price (ASP) by Type (2017-2022)1.3.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Forecasted Market Size by Type (2023-2028)1.3.3.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown in Volume by Type (2023-2028)1.3.3.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown in Value by Type (2023-2028)1.3.3.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Average Selling Price (ASP) by Type (2023-2028)1.4 Key Regions Market Size Segment by Type1.4.1 North America Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Type (2017-2022)1.4.2 Europe Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Type (2017-2022)1.4.3 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Type (2017-2022)1.4.4 Latin America Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Type (2017-2022)1.4.5 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Type (2017-2022)2 Global Preimplantation Genetic Testing for Aneuploidy Kits Market Competition by Company2.1 Global Top Players by Preimplantation Genetic Testing for Aneuploidy Kits Sales (2017-2022)2.2 Global Top Players by Preimplantation Genetic Testing for Aneuploidy Kits Revenue (2017-2022)2.3 Global Top Players Preimplantation Genetic Testing for Aneuploidy Kits Price (2017-2022)2.4 Global Top Manufacturers Preimplantation Genetic Testing for Aneuploidy Kits Manufacturing Base Distribution, Sales Area, Product Type2.5 Preimplantation Genetic Testing for Aneuploidy Kits Market Competitive Situation and Trends2.5.1 Preimplantation Genetic Testing for Aneuploidy Kits Market Concentration Rate (2017-2022)2.5.2 Global 5 and 10 Largest Manufacturers by Preimplantation Genetic Testing for Aneuploidy Kits Sales and Revenue in 20212.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Preimplantation Genetic Testing for Aneuploidy Kits as of 2021)2.7 Date of Key Manufacturers Enter into Preimplantation Genetic Testing for Aneuploidy Kits Market2.8 Key Manufacturers Preimplantation Genetic Testing for Aneuploidy Kits Product Offered2.9 Mergers & Acquisitions, Expansion3 Preimplantation Genetic Testing for Aneuploidy Kits Status and Outlook by Region3.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Market Size and CAGR by Region: 2017 VS 2021 VS 20283.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Historic Market Size by Region3.2.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Region (2017-2022)3.2.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Region (2017-2022)3.2.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales (Volume & Value) Price and Gross Margin (2017-2022)3.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Forecasted Market Size by Region3.3.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Region (2023-2028)3.3.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Region (2023-2028)3.3.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales (Volume & Value), Price and Gross Margin (2023-2028)4 Global Preimplantation Genetic Testing for Aneuploidy Kits by Application4.1 Preimplantation Genetic Testing for Aneuploidy Kits Market Segment by Application4.1.1 Public Hospital4.1.2 Private Hospital4.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Market Size by Application4.2.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Market Size Overview by Application (2017-2028)4.2.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Historic Market Size Review by Application (2017-2022)4.2.2.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown in Volume, by Application (2017-2022)4.2.2.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown in Value, by Application (2017-2022)4.2.2.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Average Selling Price (ASP) by Application (2017-2022)4.2.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Forecasted Market Size by Application (2023-2028)4.2.3.1 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown in Volume, by Application (2023-2028)4.2.3.2 Global Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown in Value, by Application (2023-2028)4.2.3.3 Global Preimplantation Genetic Testing for Aneuploidy Kits Average Selling Price (ASP) by Application (2023-2028)4.3 Key Regions Market Size Segment by Application4.3.1 North America Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Application (2017-2022)4.3.2 Europe Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Application (2017-2022)4.3.3 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Application (2017-2022)4.3.4 Latin America Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Application (2017-2022)4.3.5 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits Sales Breakdown by Application (2017-2022)5 North America Preimplantation Genetic Testing for Aneuploidy Kits by Country5.1 North America Preimplantation Genetic Testing for Aneuploidy Kits Historic Market Size by Country5.1.1 North America Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Country (2017-2022)5.1.2 North America Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Country (2017-2022)5.2 North America Preimplantation Genetic Testing for Aneuploidy Kits Forecasted Market Size by Country5.2.1 North America Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Country (2023-2028)5.2.2 North America Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Country (2023-2028)6 Europe Preimplantation Genetic Testing for Aneuploidy Kits by Country6.1 Europe Preimplantation Genetic Testing for Aneuploidy Kits Historic Market Size by Country6.1.1 Europe Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Country (2017-2022)6.1.2 Europe Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Country (2017-2022)6.2 Europe Preimplantation Genetic Testing for Aneuploidy Kits Forecasted Market Size by Country6.2.1 Europe Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Country (2023-2028)6.2.2 Europe Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Country (2023-2028)7 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits by Region7.1 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits Historic Market Size by Region7.1.1 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Region (2017-2022)7.1.2 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Region (2017-2022)7.2 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits Forecasted Market Size by Region7.2.1 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Region (2023-2028)7.2.2 Asia-Pacific Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Region (2023-2028)8 Latin America Preimplantation Genetic Testing for Aneuploidy Kits by Country8.1 Latin America Preimplantation Genetic Testing for Aneuploidy Kits Historic Market Size by Country8.1.1 Latin America Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Country (2017-2022)8.1.2 Latin America Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Country (2017-2022)8.2 Latin America Preimplantation Genetic Testing for Aneuploidy Kits Forecasted Market Size by Country8.2.1 Latin America Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Country (2023-2028)8.2.2 Latin America Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Country (2023-2028)9 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits by Country9.1 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits Historic Market Size by Country9.1.1 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Country (2017-2022)9.1.2 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Country (2017-2022)9.2 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits Forecasted Market Size by Country9.2.1 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits Sales in Volume by Country (2023-2028)9.2.2 Middle East and Africa Preimplantation Genetic Testing for Aneuploidy Kits Sales in Value by Country (2023-2028)10 Company Profiles and Key Figures in Preimplantation Genetic Testing for Aneuploidy Kits Business10.1 PerkinElmer10.1.1 PerkinElmer Corporation Information10.1.2 PerkinElmer Introduction and Business Overview10.1.3 PerkinElmer Preimplantation Genetic Testing for Aneuploidy Kits Sales, Revenue and Gross Margin (2017-2022)10.1.4 PerkinElmer Preimplantation Genetic Testing for Aneuploidy Kits Products Offered10.1.5 PerkinElmer Recent Development10.2 Illumina10.2.1 Illumina Corporation Information10.2.2 Illumina Introduction and Business Overview10.2.3 Illumina Preimplantation Genetic Testing for Aneuploidy Kits Sales, Revenue and Gross Margin (2017-2022)10.2.4 Illumina Preimplantation Genetic Testing for Aneuploidy Kits Products Offered10.2.5 Illumina Recent Development10.3 Thermo Fisher Scientific10.3.1 Thermo Fisher Scientific Corporation Information10.3.2 Thermo Fisher Scientific Introduction and Business Overview10.3.3 Thermo Fisher Scientific Preimplantation Genetic Testing for Aneuploidy Kits Sales, Revenue and Gross Margin (2017-2022)10.3.4 Thermo Fisher Scientific Preimplantation Genetic Testing for Aneuploidy Kits Products Offered10.3.5 Thermo Fisher Scientific Recent Development10.4 BASECARE10.4.1 BASECARE Corporation Information10.4.2 BASECARE Introduction and Business Overview10.4.3 BASECARE Preimplantation Genetic Testing for Aneuploidy Kits Sales, Revenue and Gross Margin (2017-2022)10.4.4 BASECARE Preimplantation Genetic Testing for Aneuploidy Kits Products Offered10.4.5 BASECARE Recent Development10.5 Peking Jabrehoo Med Tech10.5.1 Peking Jabrehoo Med Tech Corporation Information10.5.2 Peking Jabrehoo Med Tech Introduction and Business Overview10.5.3 Peking Jabrehoo Med Tech Preimplantation Genetic Testing for Aneuploidy Kits Sales, Revenue and Gross Margin (2017-2022)10.5.4 Peking Jabrehoo Med Tech Preimplantation Genetic Testing for Aneuploidy Kits Products Offered10.5.5 Peking Jabrehoo Med Tech Recent Development11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Preimplantation Genetic Testing for Aneuploidy Kits Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Preimplantation Genetic Testing for Aneuploidy Kits Industrial Chain Analysis11.4 Preimplantation Genetic Testing for Aneuploidy Kits Market Dynamics11.4.1 Preimplantation Genetic Testing for Aneuploidy Kits Industry Trends11.4.2 Preimplantation Genetic Testing for Aneuploidy Kits Market Drivers11.4.3 Preimplantation Genetic Testing for Aneuploidy Kits Market Challenges11.4.4 Preimplantation Genetic Testing for Aneuploidy Kits Market Restraints12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Preimplantation Genetic Testing for Aneuploidy Kits Distributors12.3 Preimplantation Genetic Testing for Aneuploidy Kits Downstream Customers13 Research Findings and Conclusion14 Appendix14.1 Research Methodology14.1.1 Methodology/Research Approach14.1.1.1 Research Programs/Design14.1.1.2 Market Size Estimation14.1.1.3 Market Breakdown and Data Triangulation14.1.2 Data Source14.1.2.1 Secondary Sources14.1.2.2 Primary Sources14.2 Author Details14.3 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

See original here:
Preimplantation Genetic Testing for Aneuploidy Kits Market 2022 by industry trends, statistics, key companies Growth and Regional Forecast2028 |...

Recommendation and review posted by Bethany Smith

Quadintel published a new report on the Preimplantation Genetic Testing Market. The research report consists of thorough information about demand, growth, opportunities, challenges, and restraints. In addition, it delivers an in-depth analysis of the structure and possibility of global and regional industries.

Global Preimplantation Genetic Testing Market is valued approximately USD 492.53 million in 2021 and is anticipated to grow with a healthy growth rate of more than 10.0% over the forecast period 2022-2028.

Pre-implantation genetic testing is the method that is used for the genetic analysis of embryos before implantation. It is a significant procedure because of rising cases of genetically imbalanced structures found in newborns and children. This method tests an embryo prior to implants for a particular, acknowledged genetic disorder.

Request To Download Sample of This Strategic Report: https://www.quadintel.com/request-sample/preimplantation-genetic-testing-market/QI037

The increasing number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and the growing public-private investments in the field of preimplantation genetic testing are the primary factors that are augmenting the market growth. In addition, the declining fertility rate, coupled with the rising incidences of chromosomal abnormalities with proceeding maternal age is the further factor that is surging the market demand across the globe. For instance, according to the World Bank, the fertility rate per total birth worldwide was accounted with 2.445 in 2016 and the amount is declined to 2.402 in 2019. Therefore, decreasing fertility rate is anticipated to fuels the preimplantation genetic testing demand, which, in turn, impels the market growth. However, the high procedural cost associated with preimplantation genetic testing and unfavorable government regulations impedes the growth of the market over the forecast period of 2022-2028. Also, growing awareness of assisted reproduction techniques and increasing medical tourism are anticipated to act as a catalyzing factor for the market demand during the estimated years.

The key regions considered for the global Preimplantation Genetic Testing market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing adoption of genomic techniques and growing need for IVF procedures (with decreasing fertility rates). Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as rising developments in healthcare infrastructure, as well as the rising focus of leading players on emerging markets, would create lucrative growth prospects for the Preimplantation Genetic Testing market across the Asia-Pacific region.

Request a Sample PDF copy of the report @ https://www.quadintel.com/request-sample/preimplantation-genetic-testing-market/QI037

Major market players included in this report are:

Illumina, Inc.

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

PerkinElmer, Inc.

CooperSurgical, Inc.

Beijing Genomics Institute (BGI)

Abbott Laboratories Inc.

Natera, Inc.

Good Start Genetics, Inc.

Yikon Genomics Co., Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product & Service:

Reagents & Consumables

Instruments

Software & Services

By Technology:

Next Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Fluorescent In-Situ Hybridization (FISH)

Comparative Genomic Hybridization (CGH)

Single Nucleotide Polymorphism (SNP)

By Procedure Type:

Preimplantation Genetic Screening

Preimplantation Genetic Diagnosis

By Application:

Aneuploidy

Structural Chromosomal Abnormalities

Single Gene Disorders

X-linked Disorders

HLA Typing

Gender Identification

By End User:

Maternity Centers & Fertility Clinics

Hospitals, Diagnostic Labs, and Service Providers

Research Laboratories & Academic Institutes

DOWNLOAD FREE SAMPLE REPORT https://www.quadintel.com/request-sample/preimplantation-genetic-testing-market/QI037

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2018, 2019, 2020

Base year 2021

Forecast period 2022 to 2028

Target Audience of the Global Preimplantation Genetic Testing Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.quadintel.com/request-sample/preimplantation-genetic-testing-market/QI037

Table of Contents:

Factors Influencing

The global market is forecast to witness a rapid growth, owing to increasing demand for technological advancements from end-users. Moreover, increasing investments in research and development activities, launches, partnerships, and other strategic initiatives will benefit the market. Furthermore, the growing focus of authorities towards increasing urbanization and industrialization is forecast to drive the market growth.

What aspects regarding the regional analysis Market are included in this report?

Request Full Report : https://www.quadintel.com/request-sample/preimplantation-genetic-testing-market/QI037

About Quadintel:

We are the best market research reports provider in the industry. Quadintel believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Quadintel is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Quadintel:Email: sales@quadintel.comAddress: Office 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATESTel: +1 888 212 3539 (US TOLL FREE)Website: https://www.quadintel.com/

Read the original post:
Preimplantation Genetic Testing Market [RISING TODAY] 2022 Size Analysis by Regions, Share, Industry Growth Statistics and Forecast 2030 - Taiwan News

Recommendation and review posted by Bethany Smith

Pregnancy, in this age of modern medicine, comes with a series of routinely recommended prenatal tests: At 11 weeks, a blood draw and an ultrasound to check for conditions such as Down syndrome. At 15 weeks, another blood test, for anomalies such as spina bifida. At 18 to 22, an ultrasound anatomy scan of the babys heart, brain, lungs, bones, stomach, fingers, and toes. This is when many parents learn if theyre expecting a boy or girlbut the more pressing medical reason is to look for anatomical defects, including severe ones such as missing kidneys or missing parts of the brain and skull.

With Roe v. Wade in place in America, women undergoing prenatal tests have typically had the legal right to end a pregnancy based on the information they learn. But abortion restrictions in certain statesby gestational age or by fetal anomalyhave already started limiting that choice. And if the Supreme Court overturns Roe, as seems likely, it will be further curtailed in some states. Routine parts of prenatal care could start to look quite different in states that ban abortion than in states that allow it.

Even now, laws in more than a dozen states that restrict abortion past 20 weeks are changing the use of the second-trimester anatomy scans. People are moving those tests backward, doing them earlier than is optimal, says Laura Hercher, a genetic counselor at Sarah Lawrence College who recently conducted a survey of genetic counselors in abortion-restrictive states. But the earlier the scan, the less doctors can see. Certain brain structures, such as the cavum septum pellucidum, might not develop until week 20, says Chloe Zera, an obstetrician in Massachusetts. Being unable to find this structure could indicate a brain anomaly, or just that the scan was done too early. Doctors might also pick up evidence of a heart defect but not know how severe or fixable it is. At 20 weeks, the heart is only the size of a dime.

Read: The future of abortion in post-Roe America

Six states also currently restrict abortions on the basis of genetic anomalies. These laws typically target Down syndrome, or trisomy 21, in which the presence of a third chromosome 21 can have a range of physical and mental effects, milder in some children than others. Some states laws specifically mention Down syndrome; others extend the restrictions to a much wider range of genetic anomalies, many far more life-limiting than Down syndrome. In trisomy 13, for example, the physical anomalies are so severe that most babies live only for days or weeks. More than 90 percent do not survive past their first year.

In states that currently restrict abortion based on genetic anomalies but still allow it for other reasons under Roe, patients can get an abortion if they do not mention the genetic anomaly. This puts doctors and genetic counselors in a bind. For instance, says Leilah Zahedi, a maternal-fetal-medicine physician in Tennessee, what if doctors see a severe heart defect on an ultrasound? The underlying cause of many such heart problems is Down syndrome. But Tennessee restricts abortions specifically on the basis of trisomy 21. Should doctors tell patients about the connection to Down syndrome? Should they do the genetic testing? It could help parents prepare for everything else that comes with Down syndrome. But it would make it harder for them to get an abortion, if they chose to have one. They would need to go to a different doctor who does not know about the diagnosis, and take care not to reveal it.

Many of the current abortion restrictions do contain exemptions for cases with the most dramatic medical consequences: a fatal fetal anomaly or risk to the mothers life. If Roe is overturned, many of the trigger laws that will immediately ban abortion in some states contain such exemptions as well. But what is fatal to the baby and what risk is acceptable to the mother are not entirely clear criteria. There are very few bright lines in medicine, says Cara Heuser, a maternal-fetal-medicine physician in Utah. Laws really do not allow for all the nuance we see in medicine. They ignore the uncertainty.

When it comes to fetal anomalies, its very rare we can say, This is universally fatal, Zera told me. For example, in the case of a massive brain hemorrhage that destroys most of the brain tissue but leaves the brain stem intact, the baby can breathe at birth but will need other medical care. Does fatal mean fatal in the absence of certain medical interventions? Which ones? And does an anomaly have to be fatal immediately, or within some period after birth?

Read: When a right becomes a privilege

There is ambiguity in exceptions for the life of the mother, too. A genetic counselor in Texas told me about a recent patient whose fetus was triploid, meaning it had a complete extra set of 23 chromosomes. This is one of the universally lethal conditions. But triploidy also poses an extra risk to the mother, because these pregnancies are linked to preeclampsia, or dangerously high blood pressure. Texas currently restricts abortions past about six weeks except in medical emergencies. High blood pressure may not be an immediate medical emergency, but it can become one. Whats scary about being a person who is pregnant in Texas, says the genetic counselor, whom I agreed not to name because this person feared legal retribution in the state, is that many physicians will wait to provide treatment until moms life is truly in danger. The fetus will not survive, and delaying may only increase the risk to the mother, but we have to wait until you get sick enough to deliver you. These laws create a general climate where doctors who fear prosecution may hesitate to treat the mother. Sometimes, Heuser says, that hesitation can be fatal.

If Roe is overturned and abortion is banned in many states, testing could take on a different role in prenatal care. Zahedi told me, anecdotally, of one recent patient whose doctor told her there wasnt a point to genetic screening anymore. But she doesnt actually think abortion bans will change the use of testing, even if they will limit what patients can do afterward. Most of her patients in Tennessee already do not choose abortion, she said, but the tests can provide information that inform obstetric care and prepare parents for whats to come.

Others brought up the possibility, in the long term, of insurance companies dropping coverage for prenatal tests. Cumulatively, all of these types of screenings and tests are incredibly expensive, Hercher, of Sarah Lawrence, told me. Insurance currently has a financial incentive to cover them because preventing the birth of a child with severe medical needs saves on costs down the line. But if abortion is illegal in many states, Hercher asks, will insurance companies, especially regional ones, want to continue covering these tests? Or will patients have to pay for them out of pocket? These tests are currently routine for pregnant women, but whether they stay that way in the future could depend on where you live and what you can afford.

Read the original post:
How the End of Roe Would Change Prenatal Care - The Atlantic

Recommendation and review posted by Bethany Smith

New Jersey, United States The Pediatric Genetic Testing Market Research Report is a professional asset that provides dynamic and statistical insights into regional and global markets. It includes a comprehensive study of the current scenario to safeguard the trends and prospects of the market. Pediatric Genetic Testing Research reports also track future technologies and developments. Thorough information on new products, and regional and market investments is provided in the report. This Pediatric Genetic Testing research report also scrutinizes all the elements businesses need to get unbiased data to help them understand the threats and challenges ahead of their business. The Service industry report further includes market shortcomings, stability, growth drivers, restraining factors, and opportunities over the forecast period.

Get Sample PDF Report with Table and Graphs:

https://www.a2zmarketresearch.com/sample-request/344072

The Major Manufacturers Covered in this Report @:

Eurofins Scientific, Abbott Laboratories, Invitae Corporation, Fulgent Genetics., Agilent Technologies, Inc., PerkinElmer, Inc., Thermo Fisher Scientific Inc., Genomic Diagnostics, Unilabs, LifeCell International Pvt. Ltd., Trivitron Healthcare and Baebies, Inc.

Pediatric Genetic Testing Market Overview:

This systematic research study provides an inside-out assessment of the Pediatric Genetic Testing market while proposing significant fragments of knowledge, chronic insights and industry-approved and measurably maintained Service market conjectures. Furthermore, a controlled and formal collection of assumptions and strategies was used to construct this in-depth examination.

During the development of this Pediatric Genetic Testing research report, the driving factors of the market are investigated. It also provides information on market constraints to help clients build successful businesses. The report also addresses key opportunities.

The report delivers the financial details for overall and individual Pediatric Genetic Testing market segments for the year 2022-2029 with projections and expected growth rate in percent. The report examines the value chain activities across different segments of Pediatric Genetic Testing industry. The report analyses the current state of performance of the Pediatric Genetic Testing industry and what will be performed by the global Pediatric Genetic Testing industry by 2029. The report analyzes how the covid-19 pandemic is further impeding the progress of the global Pediatric Genetic Testing industry and highlights some short-term and long-term responses by the global market players that are boosting the market gain momentum. The Pediatric Genetic Testing report presents new growth rate estimates and growth forecasts for the period.

Key Questions Answered in Global Pediatric Genetic Testing Market Report:

Get Special Discount:

https://www.a2zmarketresearch.com/discount/344072

This report provides an in-depth and broad understanding of Pediatric Genetic Testing. With accurate data covering all the key features of the current market, the report offers extensive data from key players. An audit of the state of the market is mentioned as accurate historical data for each segment is available during the forecast period. Driving forces, restraints, and opportunities are provided to help provide an improved picture of this market investment during the forecast period 2022-2029.

Some essential purposes of the Pediatric Genetic Testing market research report:

oVital Developments: Custom investigation provides the critical improvements of the Pediatric Genetic Testing market, including R&D, new item shipment, coordinated efforts, development rate, partnerships, joint efforts, and local development of rivals working in the market on a global scale and regional.

oMarket Characteristics:The report contains Pediatric Genetic Testing market highlights, income, limit, limit utilization rate, value, net, creation rate, generation, utilization, import, trade, supply, demand, cost, part of the industry in general, CAGR and gross margin. Likewise, the market report offers an exhaustive investigation of the elements and their most recent patterns, along with Service market fragments and subsections.

oInvestigative Tools:This market report incorporates the accurately considered and evaluated information of the major established players and their extension into the Pediatric Genetic Testing market by methods. Systematic tools and methodologies, for example, Porters Five Powers Investigation, Possibilities Study, and numerous other statistical investigation methods have been used to analyze the development of the key players working in the Pediatric Genetic Testing market.

oConvincingly, the Pediatric Genetic Testing report will give you an unmistakable perspective on every single market reality without the need to allude to some other research report or source of information. This report will provide all of you with the realities about the past, present, and eventual fate of the Service market.

Buy Exclusive Report: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Excerpt from:
Pediatric Genetic Testing Market Scope and overview, To Develop with Increased Global Emphasis on Industrialization 2029 | Eurofins Scientific, Abbott...

Recommendation and review posted by Bethany Smith

Your Health Matters| Meritus Health

Healthy Meritus Gardens provides a place to relax

Meritus Health volunteers see garden project as a way to relieve stresses.

Mike Lewis, The Herald-Mail

Mom jeans might be having a moment, but when it comes to your moms genes, they play an important part in your life and your health.

There are about 20,500 human genes. In recent years, weve learned so much about how genes work and why some diseases run in families, according to Kristy Hose, a nurse practitioner with advanced certifications in genetics, who works for the Meritus Center for Breast Health.

While we cant change our genes, knowing we have a higher-than-average chance of developing certain diseases can help us take steps to lower our risks.

Heres a quick reminder: We each inherit two copies of our genes, one from each parent. They are our personal instruction manual. Proteins do the work of building and maintaining our body. When genes that instruct the making of proteins develop mutations, it can cause disease. Although a mutation in a single gene can cause a disease (for example, sickle cell anemia), most diseases are the result of a combination of mutations along with lifestyle choices (such as smoking) and our environment.

Genes and disease certain known mutations raise our risk for specific diseases. Inherited mutations in the BRCA1 and BRCA2 genes, for example, raise a womans risk of developing breast and ovarian cancer.

Having these mutations does not mean that a woman will definitely develop one of these cancers. It just means shes at a higher risk of doing so, said Hose.

How much more?

According to the National Cancer Institute, about 12% of women who dont have these mutations will develop breast cancer at some point in their lives. In contrast, about 75% of women with the BRCA1 mutation and 69% of those with BRCA2 mutations will develop breast cancer by age 80.

If you have a family history of high blood pressure, you are at risk for developing high blood pressure at a young age. If a man has a father or brother with prostate cancer, it more than doubles the risk he will also have prostate cancer. Even though you cannot change your genetic makeup, knowing your family history can help you reduce your risk of developing health problems, said Hose.

Several common illnesses, including heart disease, high blood pressure, asthma, diabetes and some types of cancer run in families. Knowing your familys health history can help you determine if you have an increased risk, since inherited diseases tend to show up in distinct patterns.

According to Hose, if one or more close relatives have a disease, or they developed it at an earlier-than-average age, you may be at increased risk. When it comes to genetic testing, ask your doctor if the procedure makes sense for you. While it can be helpful for those at high risk, youll want to work with a qualified genetic counselor or go to a clinical human genomic program at a hospital where trained professionals can help you make sense of the results. Genetic testing can provide important, life-saving information.

What should you do today?

Learning about your family medical history can help you and your health care team determine whether genetic testing is likely to be of benefit. Share your family health history with your healthcare provider. In addition to making lifestyle changes (such as quitting smoking or losing weight), they may recommend additional ways to lower your risk, including medical treatments, enhance screenings, preventive medicines, or risk reducing surgery, said Hose.

At Meritus Health, we strive to provide women throughout Maryland and surrounding areas with high quality, trusted health care services. Our womens health services department offers comprehensive OB/GYN care in addition to breast health and maternity services. Find out more at MeritusHealth.com.

Here is the original post:
Knowing we have a chance of developing certain diseases can help us - Herald-Mail Media

Recommendation and review posted by Bethany Smith

Everything Genetic a life sciences company specialising in genetic testing has announced Stuart Dutton as its new Chief Financial Officer(CFO).

Stuart, who joined the team from a corporate financebackground with Sedulo, will apply his track record of growing and transforming tech and retail SMEs for the Cheshire-based business, which offers services spanning cancers, heart disease and Covid.

With a background as a qualified Chartered Accountant, Stuarts former role saw him lead a high growth team, navigating businesses through sales, mergers, acquisitions, and equity fundraisers, which ultimately led him to becoming a non-exec director for several firms.

Commenting on his new role, Stuart said: Im delighted to have been promoted to CFO atEverything Genetic, helpingthe business to work towards delivering on its ambitious growth plans.

In my former roles, I worked closely with several businesses across a variety of sectors, but I really wanted to become fully immersed within a business which had strong growth potential.

2021 was a very successful year for Everything Genetic, which saw us hit 35 million turnover. That enabled us to skip funding rounds and re-invest heavily into the businessto realise the vision of democratising testing.

Last months 5m financing deal was a great initial win for the business, to further realise its potential. Im excited to see where we can go next in further building and diversifying our cancer and wellness offering, in addition to attracting new investors.

Everything Genetics founder and CEO, James Price, said: Stuarts background as an accountant, his growth mindset and familiarity with fundraising processesmade him a perfect fit for us at Everything Genetic.

Were now in a position where we can emerge from the pandemic to re-invest into the cancer and wellness sectors addressing how the country can better utilise genetic testing to overcome some of the UKs most pressing healthcare problems.

Whether building further on the companies weve invested in, our newly expanded facilities, or our recent supplier deal with Tesco, suffice to say, weve had an exciting year so far and I cant wait to see where Stuart can help us go to next.

Everything Genetic is a leading distributor of market-leading genetic testing brands in the UK. The business has a vision to democratise genetic testing to healthcare providers and individuals, for the detection, diagnosis and treatment of cancer, cardiac and other illnesses.

Read more:
EVERYTHING GENETIC APPOINTS NEW CFO TO REALISE AMBITIOUS GROWTH TARGETS - Business Cheshire

Recommendation and review posted by Bethany Smith

HANGZHOU, China and HONG KONG, May 23, 2022 /PRNewswire/ -- New Horizon Health (6606.HK) and Prenetics Group Limited (Nasdaq: PRE, "Prenetics") has announced a strategic partnership to launch ColoClear by Circle (ColoClear), the "First Colorectal Cancer Screening Test approved in China", in Hong Kong, and for its first overseas venture in Southeast Asia. Mr. YeQing Zhu, CEO of New Horizon Health, and Mr. Danny Yeung, CEO and Co-Founder of Prenetics, have conducted joint press conference with nearly 60 mainstream media from Mainland China and Hong Kong.

New Horizon Health and Prenetics will jointly promote ColoClear in Hong Kong, Macau and Taiwan, with additional options to expand the partnership into Southeast Asian markets. Under the terms of the agreement, Prenetics will have the exclusive rights to provide ColoClear laboratory testing service and the profits from the sales of ColoClear will be shared between New Horizon Health and Prenetics. On June 8, ColoClear will be officially launched in Hong Kong.

Preneticsis a global leader in genetics and diagnostic testing, and has successfullylisted on Nasdaq in the US on May 18 via a merger with Artisan Acquisition Corp., becoming Hong Kong's first unicorn to list on the Nasdaq with the ticker "PRE". The company's pillar product pipeline covers prevention, diagnostics and personalized healthcare services, with ColoClear being the key product in disease prevention.

"New Horizon Health and Prenetics share the same vision in healthcare. Prevention and early detection, home-based healthcare, and individualized service have become the major trends in the war on canceraround the globe. We have confidence that with our joint efforts, ColoClear will become a benchmark for Asian innovation, raising awareness in cancer screening while saving many lives," said Mr. YeQing Zhu, CEO of New Horizon Health, "Cancer screening test has to pass a very high bar in order to be approved by regulatory authorities such as FDA and National Medical Products Administration (NMPA). As the only NMPA-approved cancer screening test to-date, ColoClear has enjoyed triple digit growth in 2021, the first year of its commercial launch in China. We are confident in its ability to identify colorectal cancer and precancerous lesion at early stage when it is still curable, and we look forward to working with Prenetics to benefit the broader Asian community."

Mr. Danny Yeung, CEO and Co-Founder of Prenetics also stated, "Cancer screening is an important partof Prenetics's product pipeline and believe ColoClear is a game-changer for the market. Our goal is to decentralize healthcare and bring health closer to millions of patients around the world. ColoClear has a first-mover advantage in Asia's cancer screening market, and judging from the success of Exact Sciences success with Cologuard in the USA, we look forward to deliver rapid growth of ColoClear in the future with New Horizon Health."

Colorectal cancer screening has a huge potential of growth in the Asian market. According to the Frost & Sullivan Research Report, thecolorectal cancer high-risk population in Hong Kong and Southeast Asian countries has reached USD 128 million in 2019. 94.3% of them have never conducted a screening test [1]. The Hong Kong's market in colorectal cancer screening is predicted to grow from USD 1.3 million in 2020 to USD 290 million in 2030, with a ten-year CAGR of 71.7%. On the other hand, the same market in Southeast Asia is predicted to grow from USD 33.4 million in 2020 to USD 2.79 billion in 2030, with ten-year CAGR of 55.7%. [2]

Taking the Hong Kong's marketas an example, according to the Hong Kong Cancer Registry of the Hospital Authority, colorectal cancer has been ranked asthe top two high-incidence cancers in Hong Kong since 2012, while being the second most common cause of cancer death. About one in every 6 to 7 new cancer patients suffers from colorectal cancer. In September 2016, the Department of Health of the Hong Kong SAR Government has launched the Colorectal Cancer Screening Program, subsidizing in phases eligible Hong Kong residents aged 50 to 75 to undergo screening tests for the prevention of colorectal cancer. The program is expected to benefit 300,000 individuals. Currently, FIT and colonoscopy are the most common methods for colorectal cancer detection in the Hong Kong. The average cost of a colonoscopy ranges from HKD 7,800 to HKD 10,420.

As the only cancer screening molecular test approved by the NMPA[3], ColoClear was independently developed by New Horizon Health with USD 100 million investment and over the course of 7 years, including 16 months spent in conducting China's first prospective large-scale multicenter registration trial in cancer screening. The clinical trial data shows that ColoClear has a 95.5% sensitivity for colorectal cancer and 63.5% for advanced adenoma, which is more than twice as high as the traditional FIT, proving it to be highly effective in detecting precancerous lesions. Its NPV (Negative PredictiveValue) for colorectal cancer is 99.6%, minimizing the possibility of false negative[4]. ColoClear's patented FIT-DNA technology is also the only one included in all national guidelines for colorectal cancer screening and treatment published in China so far [5-7]. As of December 31, 2021, ColoClear has been admitted and sold in over 400 hospitals within a year of receiving approval from the NMPA, and has established in-depth strategic cooperation with cross-border leading platforms includinge-commerce companies, insurance companies and private medical check-up centers. New Horizon Health holds the global rights ofColoClear.

In March 2021, New Horizon Health launched its Operation Centre in the Greater Bay Area in Nansha, Guangzhou. With a total area of 1,300 square meters, the Operation Centre is equipped with automatized sample processing and an advanced information system, with an annual capacity of 500,000 cancer screening tests.

[1] Prenetics Investor Presentation (2022.01.19)[EB/OL].

[2]Frost & Sullivan Research Report[EB/OL]. The colonoscope market is not included in this market scale data.

[3]Center for Medical Device Evaluation of NMPA. Current status and clinical technical requirements of colorectal cancer screeningproducts marketed in China and oversea [EB/OL].

[4] Center for Medical Device Evaluation of NMPA. Combination Detection Kit for KRAS Gene Mutation and BMP3/NDRG4 Gene Methylation and FOBT (PCR fluorescent probe method colloidal gold method)Innovation Device Review Report(CSZ2000050) [EB/OL].

[5] "Colorectal cancer screening in China and guidelines for early diagnosis and treatment (2020, Beijing)", Chinese Journal of Oncology, January 2021, Vol. 43 (1) [DB/OL].

[6] Chinese Society of Clinical Oncology, "The 2021 CSCO Clinical Practice Guidelines for Colorectal Cancer", People's Medical Publishing House Co., LTD, April 2021 [M/CD].

[7] Chinese Anti-Cancer Association, "Guidelines for holistic integrative management of cancer in China (CACA)", May 2022 [EB/OL].

About New Horizon Health

Founded in 2015, New Horizon Health is the pioneer and market leader in China's cancer screening market focusing on early detection of high-incidence cancers. On February 18, 2021, New Horizon Health was successfully listed on the Stock Exchange of Hong Kong under the stock code of 6606.HK, becoming the "first cancer screening stock in China".

New Horizon Health's two colorectal cancer screening products, ColoClear and Pupu Tube, as well as aH.pylori screening productUU Tube,have been approved by the National Medical Products Administration (NMPA). ColoClear is currently the only cancer screening product approved by the NMPA. UU Tube is currently the only self-conducted H.pylori screening product for home-use screening test approved in China. In addition, the company has three additional pipeline products for liver, cervical and nasopharyngeal cancer screening. The company holds global rights in all its marketed and pipeline products.

About Prenetics

Founded in 2014, Prenetics (Nasdaq: PRE) is a major global diagnostics and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars Prevention, Diagnostics and Personalized Care comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across 9 locations, including United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening; provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing.

Visit link:
New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer - PR Newswire APAC -...

Recommendation and review posted by Bethany Smith

IPO Edge and the Palm Beach Hedge Fund Association hosted a fireside chat with the CEO & Co-Founder of Prenetics Limited and the CEO & Director of Artisan Acquisition Corporation. Following the recent completion of the merger, newly-listed Prenetics now trades under the ticker PRE on Nasdaq. Topics included the SPAC merger with Artisan, managements background, an overview of Artisan, Prenetics global footprint, recent results, and plans for the future following the business combination. The live event featured Prenetics CEO & Co-Founder Danny Yeung and Artisan CEO & Director Ben Cheng joined by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a moderated video session lasting approximately 60 minutes and including a Q&A with the audience.

Watch the two highlight videos below (or click the link underneath to see the entire event):

CLICK HERE TO WATCH THE FULL 1-HOUR REPLAY

About Prenetics:

Founded in 2014, Prenetics is a major global diagnostics and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars Prevention, Diagnostics and Personalized Care comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across 9 locations, including United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening; provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. To learn more about Prenetics, visit http://www.prenetics.com.

Messrs. Yeung and Cheng discussed:

Background of Danny, Artisan and Prenetics Management Team

Global footprint, success in 2 markets and how this can be replicated in other geographies

Strong financial profile and recent results

Plan to use the proceeds and cash on balance sheet to generate sustainable revenue

Founders vision to ultimately build a health ecosystem

Story continues

About the Speakers:

Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeungs journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeungs vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to be in control of their own health.

Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeungs entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain Hui Lau Shan into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeungs life motto is Play Hard, Work Harder.

Ben Cheng is the Chief Executive Officer and Director of Artisan. He is also currently the Managing Partner at C Ventures, where he leads its sought-after deals and actively engages in major venture capital and private equity investments across the sectors of healthcare, consumer and technology. Named as Chinas Top 20 Most Outstanding Investor by Lieyun.com in 2020, Mr. Cheng has helped execute many investments in the aforementioned unicorns, such as Xpeng Motors, NIO, JD Logistics, Gojek, FTA, Xiaohongshu and Pony.ai.. Mr. Cheng is also a member of the Advisory Committee of Vertex SEA Fund, a subsidiary of Temasek Holdings, and a member of Venture Committee of Hong Kong Venture Capital and Private Equity Association.

Mr. Cheng has also served as a General Manager at New World Development since March 2016 and the Chief Investment Officer of Private Equity Department at ARTA TechFin Corporation Ltd since July 2021. Prior to his current roles, Mr. Cheng was an investment banker at Bank of America Merrill Lynch and Standard Chartered Bank. Mr. Cheng holds a bachelors degree in Quantitative Finance with honors from the Chinese University of Hong Kong

Contact:

Alan Hatfield, Director of Research

ah@capmarketsmedia.com

Twitter: @IPOEdge

Instagram: @IPOEdge

Excerpt from:
Video Highlights Covid Testing The English Premier League and Beyond: Join CEOs of Prenetics, Artisan in Fireside Chat - Yahoo Eurosport UK

Recommendation and review posted by Bethany Smith

By Peiyi Ko, Ph.D., and Margaret Dah-Tsyr Chang, Ph.D.

Digital pathology sits at the intersection of pathological diagnosis and precision medicine. In recent years, 3D pathology imaging has developed to achieve precision diagnosis, which can address some challenges in diagnosis excellence.1 Diagnosis is the foundation of effective and quality care; it has profound influence on patient outcomes.2

Using AI/ML to reduce the cognitive demands on clinicians and/or the associated diagnostic errors could help reduce adverse consequences of incorrect or delayed diagnosis in several medical specialties, such as radiology and oncology.3,4 Before leveraging AI/MLs capabilities to support analysis and interpretation of digital images, and further aiding precision medicine by enabling more individualized pathological diagnosis, identification of suitable biomarker ensembles and key parameters for proper classification of patients for a particular disease (i.e., effective companion diagnostics) is needed.5 This understanding and validation will enable application of diagnosis excellence principles, such as better linking diagnosis to treatment, providing more thoughtful interpretation of tests anticipating the probability of specific diagnostic errors, and more consistently quantifying test data to communicate benefits and limitations of diagnostic results.6

In addition, the current probability of success for oncology drug development is low despite its high costs. One of the main difficulties is achieving precision in patient screening, which relies on a pathology diagnosis. There are growing demands for precision cancer diagnosis but an insufficient number of pathologists to make the diagnoses. Therefore, the digital pathology market has grown over the past 10 years. The immuno-oncology drug market size is also increasing, yet tumor microenvironment evaluation is difficult with conventional 2D pathology.Despite playing a key role in clinical decisions for patient treatments for over 150 years, conventional 2D pathology deals with thin slides containing only a small portion of a patients biopsy (about 100 cells in a thin slide of a needle biopsy). Formalin-fixed paraformaldehyde embedded (FFPE) tissue blocks contain abundant medical information (at m resolution) about individual patients, yet the current pathology workflow using visible light reagents is not applicable for labeling spatial features of morphology or biomarker distribution in-depth. Therefore, valuable 3D pathology information of patients in FFPE remains yet to be fully utilized.

The advantages of 3D imaging over 2D can be illustrated by the comparison of computed tomography (CT) to X-ray in radiology imaging. It took quite some time to progress from digitized X-ray film to digital image to CT. One application of X-raycoupled with CT diagnosis is giving more precise parameters for evaluation of COVID-19 infected patient status.7 Digital pathology trends resemble the age of transforming X-ray film to digital images, yet development of 3D digital pathology to support precision diagnosis and precision medicine is quickly evolving. In fact, medical images of large data size have been digitized and are widely used for training AI models, among which radiology images (at mm resolution) derived from X-rays and CT images are thoroughly investigated to develop FDA-approved products.8 One example successfully implemented in hospitals to identify intracranial hemorrhage in support of better and faster clinical decisions is DeepCT, with an AI-powered triage system on head CT images developed by Deep 01 (approved by the FDA in the U.S., Taiwan, and Japan).

In the case of lung cancer and immuno-oncology therapy, a treatment modality (immune checkpoint inhibitor [ICI] therapy of nivolumab in this example) produces varied response in patients, which could be partially explained by the tumor expression of programmed-death-ligand 1 (PD-L1).9 Therefore, PD-L1 expression evaluation by a pathologist has become the standard procedure in patient selection for treatments and PD-L1 has been approved as a companion diagnostic biomarker for several drugs.

However, heterogeneity in PD-L1 expression (in lung cancer and over time) and limited biopsy samples could yield biased information for clinical evaluation and could lead to ineffective treatment. Some patients with high PD-L1 expression did not show positive response to treatment, while some with low PD-L1 expression did. Current discovery of 3D imaging technology (NSCLC 3D PD-L1 profiling) increases the sampling rate with continuous scanning of thick tissue, resulting in 100 times more pathology data from each patient, and tracing heterogeneous PD-L1 expression to give new parameters to support evaluation by the pathologists. After 3D image information is retrieved, the tissue may be reused for 2D hematoxylin and eosin (H&E) and immunohistochemistry (IHC) examination, as well as genetic testing by polymerase chain reaction (PCR). In other words, it allows the same clinical sample to be subsequently examined by multiple diagnosis methodologies and provides more integrated parameters to physicians with minimal changes in the clinical workflow.

Precision diagnosis could not only help cancer patients be matched with the most suitable treatment but also increase the success rate of new therapeutics. Continuing with the lung cancer example, IVD grade PD-L1 IHC assay is the only biomarker approved for patient screening in companion with selective indications of several ICI drugs such as pembrolizumab (Merck), nivolumab (BMS), and atezolizumab (Roche). General cutoff values of tumor proportion scores (TPS) are set as 50%, 10%, and 1% for treatment guidance.

Since PD-L1 expression in tumor tissue is heterogeneous, a pathologists choice of a single slide anywhere in the tissue for conventional IHC assay would often give a different measurement, consequently influencing the treatment plan. Some doctors think that tumor infiltrating T cells or other biomarkers in the tumor microenvironment should be taken into consideration for comprehensive diagnosis. However, it is even more challenging for pathologists to capture enough T cells or other biomarkers co-located in the same plane in the thin single slide (~4 m in thickness), not to mention a complicated calculation.

PD-L1 positive rate for diagnosis is around 20-30%; those patients diagnosed with high PD-L1 will go for ICI treatment with insurance coverage (in Taiwan where the study took place).9 But those primarily diagnosed with a low PD-L1 would need a second chance for thorough inspection of the tissue for the PD-L1 signature to see if they are truly PD-L1 negative. Using computer-assisted PD-L1 quantitation method (i.e., an AI model for tumor cell recognition and PD-L1 positive cell identification) co-developed with pathologists to support diagnosis, a 3D PD-L1 TPS score was generated to categorize results with maximum, minimum, and average of values and compared to the 2D TPS scores and classification. Reclassifications lead to two cases passing the threshold for receiving treatment with medication concordance. This study supports the potential value of using an extra dimension in improving precision in PD-L1 measurement and applying 3D pathology evaluation to the FFPE specimen, which helps address the problem of uncertainties in diagnosis due to insufficient sampling (hence, inconsistencies) and allows patients to have the choice to receive treatment should the improved test results indicate it is appropriate. With further combination with other pathological data and leveraging AI/ML technologies, the 3D pathology based panoramic platform might aid in personalized or more tailored medicine in the future.

In addition to having approved many AI/ML-based medical technologies via 510(k) clearance, premarket approval, and de novo pathways,4 the U.S. FDA, Health Canada, and the U.K.s MHRA have joined efforts to identify 10 guiding principles that will inform the development of good machine learning practice (GMLP) to promote safe, effective, and high-quality devices that use AI/ML.10 This is to address the unique nature of these products (i.e., complex, iterative, and data-driven) and the challenges/special considerations associated with them. Accuracy and consistency of diagnosis, prevention of bias to improve healthcare outcome and reduce costs, as well as articulating the safety and effectiveness of the products are key considerations for companies developing these types of solutions.11

In Part 2 of this article series, we will discuss considerations for collaboration between an AI/ML tech company and a hospital to develop and validate a technology solution for improving healthcare outcomes. Some potential barriers to and options for implementation and adoption of this type of solution in healthcare settings will also be discussed.

References:

About The Authors:

Peiyi Ko, Ph.D., CHFP, is founder and consultant at KoCreation Design LLC. Since 2017, she has researched and promoted integrated quality and adoption of technology by the life science industry. She has executed and managed projects, presented at conferences and university classes, and led workshops. She obtained her Ph.D. from the University of California, Berkeley, where she also completed the Engineering, Business, and Sustainability Certificate and the Management of Technology Certificate programs in 2011. You can reach her atinfo@kocreationdesign.com and connect on LinkedIn.

Margaret Dah-Tsyr Chang, Ph.D., is founder and Chief Strategy Officer of JelloX Biotech Inc. She has expertise in molecular biology and protein engineering supporting biotech-academic collaboration and biomedical translation from university to industry. She has executed and managed research and education projects, offered courses, promoted IP engineering and technology licensing, and organized conferences at National Tsing Hua University, Taiwan. She received her Ph.D. from the Department of Chemistry, Johns Hopkins University, and immediately established the first undergraduate molecular biology laboratory in Taiwan in 1993. You can reach her at margaretdtchang@jellox.com.

The rest is here:
Intelligent Analysis of 3D Pathology Imaging Adds New Dimension To Precision Diagnosis - Med Device Online

Recommendation and review posted by Bethany Smith

There are estimated to be less than 150 Malayan Tigers left in the wild.

JACKSONVILLE, Fla. A critically endangered male Malayan Tiger is now calling the Jacksonville Zoo and Gardens his new home.

The zoo announced the addition of Bashir, a 13-year-old, male critically endangered Malayan Tiger in a press release Tuesday.

The zoo says he actually arrived in early April and has been adjusting well to his new home.

Bashir is acclimating nicely and at his own pace, said Tirzah Nichols, Senior Mammal Keeper. We pay close attention to his comfort levels in his new surroundings, monitor his progress and only introduce him to new areas when he is ready.

The keeper staff at the Zoo say they have been spending time developing a positive relationship with Bashir and establishing trust while he settles into his new home.

According to the staff, Bashir is relaxed, but very charismatic, vocal and expressive. He enjoys his toys and exploring new environments.

Bashir joined the Zoo through the Species Survival Plan (SSP) between accredited zoos and aquariums. SSP looks at the genetics of captive populations to make the best pairings to ensure these endangered species thrive.

Bashir is recommended to breed with the zoo's current Malayan female, Cinta.

There are estimated to be less than 150 Malayan Tigers left in the wild.

Jacksonville Zoo and Gardens is excited to participate in such significant conversation efforts, said Nichols. With a critically endangered status, species like the Malayan Tiger can significantly benefit from our joined efforts with other institutions to help ensure their future survival.

Bashir made his debut on May 5, in the award-winning Land of the Tiger exhibit.

Jacksonville Zoo and Gardens is open daily.

Visit jacksonvillezoo.org for admission tickets.

Continued here:
Endangered Malayan Tiger comes to the Jacksonville Zoo and Gardens - FirstCoastNews.com WTLV-WJXX

Recommendation and review posted by Bethany Smith

The latest competent intelligence report published by WMR with the title An increase in demand and Opportunities for Global BRCA1 & BRCA2 Gene Testing Market 2022 provides a sorted image of the BRCA1 & BRCA2 Gene Testing industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to play a significant role in making a gradual impact on the global economy. The report presents and showcases a dynamic vision of the global scenario in terms of market size, market statistics, and competitive situation.

At present, the BRCA1 & BRCA2 Gene Testing market is possessing its presence over the globe. The Research report presents a complete judgment of the market which consists of future trends, growth factors, consumption, production volume, CAGR value, attentive opinions, profit margin, price, and industry-validated market data. This report helps the individuals and the market competitors to predict future profitability and to make critical decisions for business growth.

A sample report can be viewed by visiting (UseCorporate eMail ID to Get Higher Priority) at:https://www.worldwidemarketreports.com/sample/761942

Scope of BRCA1 & BRCA2 Gene Testing Market:

Emerging trends, The report on the BRCA1 & BRCA2 Gene Testing market gives the complete picture of demands and opportunities for the future that are beneficial for individuals and stakeholders in the market. This report determines the market value and the growth rate based on the key market dynamics as well as the growth improving factors. The entire study is based on the latest industry news, market trends, and growth probability. It also consists of a deep analysis of the market and competing scenario along with the SWOT analysis of the well-known competitors.

The Leading Players involved in the global BRCA1 & BRCA2 Gene Testing market are:

SOPHiA GENETICS Breastcancer.org Laboratory Corporation of America Holdings Myriad Genetics Inc Testing.com Invitae Corporation Susan G. Komen Mayo Foundation for Medical Education and Research (MFMER)

Segmentation by Type:

Breast Cancer Male Breast Cancer Ovarian Cancer Prostate Cancer Pancreatic Cancer Melanoma Acute Myeloid Leukemia Peritoneal Cancer

Segmentation by Applications:

BRCA1 Genetic Testing BRCA2 Genetic Testing

Get PDF Brochure Here by Clicking:https://www.worldwidemarketreports.com/sample/761942

Global BRCA1 & BRCA2 Gene Testing Market Regional Analysis:

The research study has segregated the global BRCA1 & BRCA2 Gene Testing industry into segments, including product type, application, and vertical, to broaden the overall understanding of the industry. This assessment has been carried out on the basis of size, share, and CAGR. Additionally, regional analysis has been done by the experts stressing the growth potential of the key regions and countries. The report also encompasses accurate and reliable figures based on the BRCA1 & BRCA2 Gene Testing consumption and production in key regions.

North America: USA, Canada, and Mexico, etc.Asia-Pacific: China, Japan, Korea, India, and Southeast AsiaThe Middle East and Africa: Saudi Arabia, the UAE, Egypt, Turkey, Nigeria, and South AfricaEurope: Germany, France, the UK, Russia, and ItalySouth America: Brazil, Argentina, Columbia, etc.

The report helps in the providing of a wider introduction of the market and also helps in dealing with the detailed methodology of research for the calculation of the size and forecasts of the market. The sources of secondary data are used and the primary inputs that are taken for the validation of data. This section also helps in the outlines of the several segments that have also been covered as being a part of the report. Additionally, the Research Methodology reviews tend of providing the calculation for determining the inclinations of the global market.

Get customization &Inquire AboutDiscount:https://www.worldwidemarketreports.com/quiry/761942

Some of the Major Points of TOC cover:

Chapter 1: Techniques & Scope

1.1 Definition and forecast parameters1.2 Methodology and forecast parameters1.3 Information Sources

Chapter 2: Latest Trends Summary

2.1 Regional trends2.2 Product trends2.3 End-use trends2.4 Business trends

Chapter 3: BRCA1 & BRCA2 Gene Testing Industry Insights

3.1 Industry fragmentation3.2 Industry landscape3.3 Vendor matrix3.4 Technological and innovative landscape

Chapter 4: BRCA1 & BRCA2 Gene Testing Market, By Region

Chapter 5: Company Profiles

5.1 Company Overview5.2 Financial elements5.3 Product Landscape5.4 SWOT Analysis5.5 Systematic Outlook

Chapter 6: Assumptions and Acronyms

Chapter 7: Research Methodology

Chapter 8: Contact (Continue . . .)

Purchase of BRCA1 & BRCA2 Gene Testing Market Report at:https://www.worldwidemarketreports.com/buy/761942

Finally, the report BRCA1 & BRCA2 Gene Testing Market 2022 provides an industry development game plan, the industry information source, research findings, appendix, and conclusion. The report offers precise clarification of the market by highlighting the market manufacturing procedure, market competitors, sellers and merchants classification, the implementation of innovation, business improvement designs. All these details will reassure clients of future plans and actions intended to compete with other players in the market. Further, the most recent improvements in the market are displayed.

Contact Us:

Worldwide Market Reports,Tel: U.S. +1-415-871-0703U.K. +44-203-289-4040Japan +81-50-5539-1737Email: sales@worldwidemarketreports.comWebsite: https://www.worldwidemarketreports.com/

View post:
According to the Latest Report: BRCA1 & BRCA2 Gene Testing Market Is Expected Significant Growth, Forecast From 2022 to 2028: SOPHiA GENETICS,...

Recommendation and review posted by Bethany Smith

For close to a hundred years, it has been one of natures greatest whodunnits involving egg forgeries and plenty of deception.

It is all part of an evolving arms race taking place out on the grasslands of Africa between a nondescript brood parasite and the host species it preys on.

The parasite is a small sparrow-sized bird called a cuckoo finch whose reproductive cycle involves sneaking into the nests of other birds and laying its eggs.

For the cuckoo finch to be successful, the egg needs to be almost identical to its host. If the forgery is spotted in time, the host species will spear the egg with its beak, remove it from its nest and drop it in the grass.

It is the cuckoo finchs success that is the mystery.

Zweli Mkhizes race against time and the Special Investigating Unit

Generations of female cuckoo finches have evolved the ability to broadly mimic the egg appearance of several different host species, each of which lays a distinct range of egg types. How cuckoo finches and other brood parasitic bird species are able to evolve such specialised adaptations to different host species, despite interbreeding between males and females raised by different hosts, has been a long-standing mystery.

This has puzzled scientists because the usual mix of genetics inherited by both parents should cause the colours of these eggs to vary from mother to daughter, depending on who the father was.

Now genetic research by an international team of scientists led by Prof Claire Spottiswoode from the University of Cape Towns Percy FitzPatrick Institute of African Ornithology and the University of Cambridges Department of Zoology believe they have cracked the mystery and what they have found is mixed news to those avian egg forgers.

Cuckoo finches are rather enigmatic birds, and many birdwatchers have never seen one, says Spottiswoode, who has been studying the birds in southern Zambia, together with colleagues from the local community.

The cuckoo finch is found across sub-Saharan Africa, favouring grasslands particularly close to water sources. And even though the bird is widespread, ornithologists arent even sure how many host species the cuckoo finch has.

There could be as many as 10 host species, but the female cuckoo finch will only target one of these in her lifetime.

For the female cuckoo finch to sneak her egg into a nest requires excellent timing and a keen eye. She first needs to spot the nest of the parents that are going to rear her chick.

They have a small window of opportunity; they need to get their own egg in during the laying period of the host, explains Spottiswoode.

She and her colleagues found that the secret to the cuckoo finchs ability to produce eggs that fool their hosts has to do with the W chromosome that is passed from mother to daughter. The W chromosome is similar to the male-specific Y chromosome in humans, in that it is carried by one sex only. Except in birds, it is carried only in females rather than in males.

So, that means theres a chunk of DNA that is passed down from mother to daughter, largely unaffected by gene flow from the father. So crucially, this could allow different lineages of females to evolve specialised adaptations that can be carried on, or is regulated by that chromosome that can be passed on to their daughters regardless of who the daughters father was, explains Spottiswoode.

Our data from the cuckoo finch in Zambia exactly matches that long-standing idea, because we see that females laying different egg types belong to distinct maternal lineages that diverged from each other hundreds of thousands to millions of years ago. Yet they all remain part of the same species, because maternal inheritance means that these specialised females can mate randomly with any cuckoo finch male, regardless of what host species he was raised by, and still pass on their specialised adaptations to their daughters.

Their findings were published in a recent issue of the academic journal Proceedings of the National Academy of Sciences.

The discovery validates an idea geneticist Reginald Punnett first suggested in 1933. He had hypothesised that European common cuckoos inherited their egg mimicry abilities from their mothers.

Their research involved collecting DNA samples from 196 cuckoo finches from 141 nests at their field site in southern Zambia.

The cuckoo finches were located in the nests belonging to four different grass warbler species. Here, the researchers saw ongoing one-upmanship between host and parasite.

To counteract the cuckoo finches, the grass warblers have become skilled quality controllers. They are quick to reject eggs that differ from their own and they have a secret weapon each female has a unique signature she leaves on her eggs. Its a kind of biological watermark that helps her detect intruder eggs.

Cuckoo finches, in turn, have evolved mimicry of some but not all of these host egg signatures.

An example of this has been shown in previous studies in one of the cuckoo finchs hosts, the tawny-flanked prinia, that produces a diversity of egg colours. Cuckoo finches lay eggs mimicking red, blue and white prinia eggs, but not the rich olive green eggs laid by some prinia females.

The new work suggests a likely hypothesis for why cuckoo finches are sometimes unable to mimic all the signature types that hosts can produce: maternal inheritance slows down evolution by forgoing the diversity produced by genetic mixing between males and males.

This likely explains why cuckoo finches cant forge certain egg types produced by their hosts, which the study shows inherit their egg appearance from both parents.

So while maternal inheritance gives parasites an important advantage in allowing them to evolve distinct mimicry of multiple distinct hosts, this could also have a downside in slowing down their ability to evolve to keep up in evolutionary arms races with their hosts.

This arms race between host and brood parasite isnt just about finding ways of passing and spotting egg forgeries. Hosts have evolved other methods to stop brood parasites from laying their eggs in their nests. Some species of weavers, for instance, have lengthened the entrances to their nests, making it harder for cuckoos to enter.

I have seen on three occasions where weavers have trapped cuckoos trying to get into their nest. With those entrance tunnels they sometimes get stuck.

And when this happens, the whole community of weavers will rush in and effectively weave the cuckoo into the nest. They seal her in, says ornithologist Geoff Lockwood, who wasnt involved in the cuckoo finch study.

Brood parasites are fighting back too, by using new methods of deception.

What we think might be happening with some of the honey guides, is that the male hangs around causing trouble, showing himself and driving the host species frantic. They then go and chase it away, and while the chase is on, the female sneaks in, drops an egg and takes one of the hosts eggs away, explains Lockwood.

But this is a war the brood parasite cant win outright.

If they are too successful, then the host population is depleted to the point where its almost impossible to find a nest then the cuckoo or brood parasite will also go into massive decline, says Lockwood. DM/OBP

Related Articles

Read the original post:
EGGCELLENT FORGERY: Scientists crack the mystery of how the cuckoo finch gets other birds to raise its brood - Daily Maverick

Recommendation and review posted by Bethany Smith

Adrion JR, White PS, Montooth KL (2016) The roles of compensatory evolution and constraint in aminoacyl tRNA synthetase evolution. Mol Biol Evol 33:152161

CAS PubMed Article Google Scholar

Allio R, Donega S, Galtier N, Nabholz B (2017) Large variation in the ratio of mitochondrial to nuclear mutation rate across animals: implications for genetic diversity and the use of mitochondrial DNA as a molecular marker. Mol Biol Evol 34:27622772

CAS PubMed Article Google Scholar

Allison TM, Radzvilavicius AL, Dowling DK (2021) Selection for biparental inheritance of mitochondria under hybridization and mitonuclear fitness interactions. Proc Biol Sci 288:20211600

CAS PubMed PubMed Central Google Scholar

Arrieta-Montiel MP, Mackenzie SA (2011) Plant mitochondrial genomes and recombination. In: Kempken F (ed.) Plant Mitochondria. Springer New York, New York, NY, p 6582

Chapter Google Scholar

Ashar FN, Zhang Y, Longchamps RJ, Lane J, Moes A, Grove ML et al. (2017) Association of mitochondrial DNA copy number with cardiovascular disease. JAMA Cardiol 2:12471255

PubMed PubMed Central Article Google Scholar

Baldo L, Bordenstein S, Wernegreen JJ, Werren JH(2006) Widespread recombination throughout Wolbachia genomes Mol Biol Evol 23:437449

CAS PubMed Article Google Scholar

Barbrook AC, Voolstra CR, Howe CJ (2014) The chloroplast genome of a Symbiodinium sp. clade C3 isolate. Protist 165:113

CAS PubMed Article Google Scholar

Barr CM, Neiman M, Taylor DR (2005) Inheritance and recombination of mitochondrial genomes in plants, fungi and animals. N. Phytol 168:3950

CAS Article Google Scholar

Barreto FS, Watson ET, Lima TG, Willett CS, Edmands S, Li W et al(2018) Genomic signatures of mitonuclear coevolution across populations of Tigriopus californicus Nat Ecol Evolution 2:12501257

Article Google Scholar

Baur E (1908) Das Wesen und die Erblichkeitsverhltnisse der Varietates albomarginatae hort. vonPelargonium zonale. Z fr Indukt Abstamm- und Vererbungslehre 1:330351

Google Scholar

Beck EA, Thompson AC, Sharbrough J, Brud E, Llopart A (2015) Gene flow between Drosophila yakuba and Drosophila santomea in subunit V of cytochrome c oxidase: A potential case of cytonuclear cointrogression. Evolution 69:19731986

CAS PubMed PubMed Central Article Google Scholar

Bennett GM, Moran NA (2013) Small, smaller, smallest: the origins and evolution of ancient dual symbioses in a Phloem-feeding insect. Genome Biol Evol 5:16751688

PubMed PubMed Central Article CAS Google Scholar

Bensasson D, Zhang D-X, Hartl DL, Hewitt GM (2001) Mitochondrial pseudogenes: evolutions misplaced witnesses. Trends Ecol Evol 16:314321

CAS PubMed Article Google Scholar

Bentley KE, Mandel JR, McCauley DE (2010) Paternal leakage and heteroplasmy of mitochondrial genomes in Silene vulgaris: evidence from experimental crosses. Genetics 185:961968

Birky Jr CW (2001) The inheritance of genes in mitochondria and chloroplasts: laws, mechanisms, and models. Annu Rev Genet 35:125148

CAS PubMed Article Google Scholar

Birky CW, Strausberg RL, Forster JL, Perlman PS (1978) Vegetative segregation of mitochondria in yeast: Estimating parameters using a random model. Mol Gen Genet 158:251261

Article Google Scholar

Blokhin A, Vyshkina T, Komoly S, Kalman B (2008) Variations in mitochondrial DNA copy numbers in MS brains. J Mol Neurosci 35:283287

CAS PubMed Article Google Scholar

Bock DG, Andrew RL, Rieseberg LH (2014) On the adaptive value of cytoplasmic genomes in plants. Mol Ecol 23:48994911

PubMed Article Google Scholar

Boore JL (1999) Animal mitochondrial genomes. Nucleic Acids Res 27:17671780

CAS PubMed PubMed Central Article Google Scholar

Bordenstein SR, OHara FP, Werren JH(2001) Wolbachia-induced incompatibility precedes other hybrid incompatibilities in Nasonia Nature 409:707710

CAS PubMed Article Google Scholar

Boulet L, Karpati G, Shoubridge EA (1992) Distribution and threshold expression of the tRNA(Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 51:11871200

CAS PubMed PubMed Central Google Scholar

Boyd BM, Chevignon G, Patel V, Oliver KM, Strand MR (2021) Evolutionary genomics of APSE: a tailed phage that lysogenically converts the bacterium Hamiltonella defensa into a heritable protective symbiont of aphids. Virol J 18:219

Breton S, Beaupr HD, Stewart DT, Hoeh WR, Blier PU (2007) The unusual system of doubly uniparental inheritance of mtDNA: isnt one enough? Trends Genet 23:465474

CAS PubMed Article Google Scholar

Breton S, Burger G, Stewart DT, Blier PU (2006) Comparative analysis of gender-associated complete mitochondrial genomes in marine mussels (Mytilus spp.). Genetics 172:11071119

CAS PubMed PubMed Central Article Google Scholar

Brown TA, Cecconi C, Tkachuk AN, Bustamante C, Clayton DA (2005) Replication of mitochondrial DNA occurs by strand displacement with alternative light-strand origins, not via a strand-coupled mechanism. Genes Dev 19:24662476

CAS PubMed PubMed Central Article Google Scholar

Brown WM, George Jr M, Wilson AC (1979) Rapid evolution of animal mitochondrial DNA. Proc Natl Acad Sci USA 76:19671971

CAS PubMed PubMed Central Article Google Scholar

Broz AK, Waneka G, Wu Z, Fernandes Gyorfy M, Sloan DB (2021) Detecting de novo mitochondrial mutations in angiosperms with highly divergent evolutionary rates. Genetics 218:iyab039

Burton RS (1990) Hybrid breakdown in developmental time in the copepod Tigriopus californicus. Evolution 44:18141822

Burton RS, Lee BN(1994) Nuclear and mitochondrial gene genealogies and allozyme polymorphism across a major phylogeographic break in the copepod Tigriopus californicus Proc Natl Acad Sci USA 91:51975201

CAS PubMed PubMed Central Article Google Scholar

Burzyski A, Zbawicka M, Skibinski DOF, Wenne R(2003) Evidence for recombination of mtDNA in the marine mussel Mytilus trossulus from the Baltic. Mol Biol Evol 20:388392

PubMed Article Google Scholar

Camus MF, Wolff JN, Sgr CM, Dowling DK(2017) Experimental support that natural selection has shaped the latitudinal distribution of mitochondrial haplotypes in Australian Drosophila melanogaster Mol Biol Evol 34:26002612

CAS PubMed Article Google Scholar

Carelli V, Maresca A, Caporali L, Trifunov S, Zanna C, Rugolo M (2015) Mitochondria: Biogenesis and mitophagy balance in segregation and clonal expansion of mitochondrial DNA mutations. Int J Biochem Cell Biol 63:2124

CAS PubMed Article Google Scholar

Carnegie L, Reuter M, Fowler K, Lane N, Camus MF(2021) Mothers curse is pervasive across a large mitonuclear Drosophila panel Evol Lett 5:230239

PubMed PubMed Central Article Google Scholar

Carrier TJ, Leigh BA, Deaker DJ, Devens HR, Wray GA, Bordenstein SR et al. (2021) Microbiome reduction and endosymbiont gain from a switch in sea urchin life history. Proc Natl Acad Sci USA 118:e2022023118

Cato SA, Richardson TE (1996) Inter- and intraspecific polymorphism at chloroplast SSR loci and the inheritance of plastids in Pinus radiata D. Don. Theor Appl Genet 93:587592

Cerutti H, Johnson AM, Boynton JE, Gillham NW(1995) Inhibition of chloroplast DNA recombination and repair by dominant negative mutants of Escherichia coli RecA Mol Cell Biol 15:30033011

CAS PubMed PubMed Central Article Google Scholar

Charlat S, Hornett EA, Fullard JH, Davies N, Roderick GK, Wedell N et al. (2007) Extraordinary flux in sex ratio. Science 317:214

CAS PubMed Article Google Scholar

Charlat S, Reuter M, Dyson EA, Hornett EA, Duplouy A, Davies N et al. (2007) Male-killing bacteria trigger a cycle of increasing male fatigue and female promiscuity. Curr Biol 17:273277

CAS PubMed Article Google Scholar

Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J Biol Chem 267:166172

CAS PubMed Article Google Scholar

Chevigny N, Schatz-Daas D, Lotfi F, Gualberto JM (2020) DNA repair and the stability of the plant mitochondrial genome. Int J Mol Sci 21:328

Chiu W-L, Stubbe W, Sears BB(1988) Plastid inheritance in Oenothera: organelle genome modifies the extent of biparental plastid transmission Curr Genet 13:181189

CAS Article Google Scholar

Christie JR, Beekman M (2017) Selective sweeps of mitochondrial DNA can drive the evolution of uniparental inheritance. Evolution 71:20902099

CAS PubMed Article Google Scholar

Christie JR, Schaerf TM, Beekman M (2015) Selection against heteroplasmy explains the evolution of uniparental inheritance of mitochondria. PLoS Genet 11:e1005112

PubMed PubMed Central Article CAS Google Scholar

Ciborowski KL, Consuegra S, Garca de Leniz C, Beaumont MA, Wang J, Jordan WC (2007) Rare and fleeting: an example of interspecific recombination in animal mitochondrial DNA. Biol Lett 3:554557

CAS PubMed PubMed Central Article Google Scholar

Clark KA, Howe DK, Gafner K, Kusuma D, Ping S, Estes S et al(2012) Selfish little circles: transmission bias and evolution of large deletion-bearing mitochondrial DNA in Caenorhabditis briggsae nematodes PLoS One 7:e41433

CAS PubMed PubMed Central Article Google Scholar

Clay Montier LL, Deng JJ, Bai Y (2009) Number matters: control of mammalian mitochondrial DNA copy number. J Genet Genomics 36:125131

PubMed PubMed Central Article CAS Google Scholar

Cleland RE (1963) The cytogenetics of Oenothera. Adv Genet 11:147237

Cole LW, Guo W, Mower JP, Palmer JD (2018) High and variable rates of repeat-mediated mitochondrial genome rearrangement in a genus of plants. Mol Biol Evol 35:27732785

CAS PubMed Google Scholar

Correns C (1909) Zur kenntnis der rolle von kern und plasma bei der vererbung. Z Indukt Abstamm Vererbungsl 2:331340

Google Scholar

Dahal S, Dubey S, Raghavan SC (2018) Homologous recombination-mediated repair of DNA double-strand breaks operates in mammalian mitochondria. Cell Mol Life Sci 75:16411655

CAS PubMed Article Google Scholar

Dai B, Guo H, Huang C, Zhang X, Lin Z (2016) Genomic heterozygosity and hybrid breakdown in cotton (Gossypium): different traits, different effects. BMC Genet 17:58

Davila JI, Arrieta-Montiel MP, Wamboldt Y, Cao J, Hagmann J, Shedge V et al. (2011) Double-strand break repair processes drive evolution of the mitochondrial genome in Arabidopsis. BMC Biol 9:64

Day A, Madesis P (2007) DNA replication, recombination, and repair in plastids. In: Bock R (ed) Cell and Molecular Biology of Plastids. Springer Berlin Heidelberg, Berlin, Heidelberg, p 65119

Chapter Google Scholar

De Vooght L, Caljon G, Van Hees J, Van Den Abbeele J (2015) Paternal transmission of a secondary symbiont during mating in the viviparous tsetse fly. Mol Biol Evol 32:19771980

PubMed PubMed Central Article CAS Google Scholar

DeBalsi KL, Hoff KE, Copeland WC (2017) Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases. Ageing Res Rev 33:89104

CAS PubMed Article Google Scholar

Go here to see the original:
Inheritance through the cytoplasm | Heredity - Nature.com

Recommendation and review posted by Bethany Smith

It could be in their genes, posits Tangye. Genetic influences are either making people vulnerable to really severe disease but may also contribute to resistance there are populations of people who probably should have been infected and sick but werent.

Exactly which genes have a protective effect is part of an international research project called the COVID Human Genetic Effort, that Christodoulou is involved with.

We are collecting information and DNA from individuals who have been hyperexposed to COVID but who dont seem to contract COVID for example, living in a household where multiple family members were infected, but one member of the household wasnt to see if genetic factors can be identified that might offer protection against COVID infection, says Christodoulou, who is also the chair of Genomic Medicine at the University of Melbourne.

While researchers keep searching for the genetic clues, a new study published at the end of April, found booster shots can increase the range of immune cells, called memory B cells, making them more effective at neutralising COVID.

With any infection or vaccination, our body responds and then forgets the virus, explains Tangye, but becomes better at responding with repeated exposure. The first and second doses are like the training, getting your immune system into good shape and ready to take off and the third really gives you the protection you are primed and ready to go.

So if someone who has recently been vaccinated is exposed to COVID, they may be protected. If they have been boosted, this may provide even more protection, at least for a time.

Loading

The degree of exposure how long we were in contact with someone and whether we were inside or out will also make a difference, as will our behaviour.

People have become much more cognisant of social distancing and washing their hands and wearing masks. There are those non-pharmaceutical interventions people have embraced, Tangye says.

As for how healthy you are generally, that unfortunately wont make us resistant to catching COVID.

We regularly hear of otherwise young, fit and healthy individuals contracting very severe COVID, says Christodoulou. For those otherwise healthy people we know that there are some factors that are associated with this, e.g., having so-called auto-antibodies to type 1 interferons (type 1 interferons are the first line of defence against COVID) or having mutations in genes that are involved in production and function of type 1 interferons.

Being healthy is good. But healthy people are still getting sick. Its not a panacea.

Interestingly, Tangye adds that there are people who naturally have this type 1 interferon pathway turned up a little bit: That can be pathogenic they can get these inflammatory diseases that dont have a defined triggerthese non-infectious, spontaneous flares for no good reason but people with those conditions may well have some resistance to COVID just because they have that innate immune response primed.

These people account for only a fraction of never COVIDs. For the rest, it seems to come down to a combination of immunity, genetics, environment and luck.

Being healthy all round puts you in better shape against infectious diseases and lifestyle disease, says Tangye. Being healthy is good. But healthy people are still getting sick. Its not a panacea.

Most of us may not be able to do much to avoid the virus, but we can still look to never COVIDs for some answers.

Loading

If we can identify genetic reasons why people dont get COVID, it may help inform ways by which SARS COV2 enters or attacks our cells remember viruses are hopeless on their own. They need all the machinery of our cells to be disease-causing, explains Tangye.

So if we can disrupt the human cell processes without too many adverse events we could be better at stopping viral infection.

Make the most of your health, relationships, fitness and nutrition with our Live Well newsletter. Get it in your inbox every Monday.

Read more here:
Havent had COVID yet? Its got to do with more than your T cells - Sydney Morning Herald

Recommendation and review posted by Bethany Smith

Throughout evolution, humans have looked for traits that would grant them a better chance at survival and reproduction. Larger women signified health, the ability to bear children, money, and food therefore, a better chance at survival and continuing on your lineage.

The traits that evolution deemed desirable still linger for us subconsciously, but act alongside many other factors, such as the mass influence of cultural standards of beauty.

In various cultures, whatever is in vogue, people have tried to manipulate their bodies to look that way, Cristen Harris, associate teaching professor of epidemiology, said. Whether it be the tiny waist, so the Victorian era, or even back in the 40s and 50s. In this country, in the middle of [the] Marilyn Monroe days, there were ads for dietary supplements for weight gainers for women to be voluptuous.

As time has gone on and moved past the cultural phase of idealizing bodies like Marilyn Monroes, we have seen an increase in idealizing a body type that, for most women, is unattainable.

The general public and media tell us that we should (ideally) have all of the following: big boobs and a big butt (but not too big that it looks fake; it has to look natural), flat stomach, toned (but not muscular cause thats too masculine), petite and short frame, no hair (except for on your head), and skinny but not too skinny (dont wanna look sickly).

It should be noted that although Im focusing on young women's struggles, cultural standards of beauty affect people of all ages, races, and genders.

We do see evidence that 3-to-5-year-olds express concern about not getting too fat, Harris said. Then we see that persist throughout adolescence, throughout college years or young adulthood, [and] we're seeing eating disorders and body image concerns continue through to older age, people in their 70s and older that are still concerned about dieting, to lose weight to fit into that mold.

Young women, especially college-age women, are under a microscope to fit within this mold, with the popular notion that we are in our prime or peak as far as looks go.

According to a 2021 study by The Emily Program, any college student, whether male, female, or nonbinary, has an increased risk of developing some kind of eating disorder. However, women and gender minorities are almost four times more likely to show symptoms of an eating disorder than cisgender men.

On top of this, college women are going through the phase of their lives where they are under the most pressure to appeal to the male gaze.

Hookup culture at any college is without shame and very obvious. There are many opportunities on a weekly basis for people to hook up, and if you are not actively doing this, it can be hard not to question if there is something you need to change about yourself.

There is a concept in the Greek system called gads (grab-a-date), where you can only get invited to a party if a boy asks you. As much as we all want to not be seen as pick me girls, its almost impossible not to question yourself when youre not picked.

Some might say, as a solution to these insecurities, If you arent happy with the way you look or your body, just fix it by working out and dieting.

This fix it mentality simplifies an extremely complicated issue. It is incredibly harmful and not realistic whatsoever. For some people, health-wise, nothing needs to be fixed.

I think part of the issue is that people seem to draw a straight line between body size and health, Harris said. There are numerous factors that determine whether a person is healthy or not, and how do we really even define that? Is it the absence of disease? What about a person who has had cancer and they're in remission?

The health benefits, both physically and mentally, of moving your body should not be ignored. However, given the health repercussions of neglecting your body, our understanding of health has become incredibly skewed.

Research shows that about a third of people who are in a normal body size according to BMI are metabolically unhealthy, and about a third of people who are in overweight or obese body size according to BMI are metabolically healthy, Harris said.

All bodies metabolize differently. While one inactive woman could eat, let's say, five full meals per day and stay at 115 pounds, another woman could be working out constantly, consistently gaining weight, and only eating one or two meals a day because of factors such as stress, genetics, or medications.

Many people are not aware of the negative effects of dieting, and how the very act of relentlessly trying to fit into the desired mold of beauty and health actually makes you more unhealthy.

Studies show that the consequences of eating disorders and disordered eating are incredibly consequential to a woman's long-term health reproductive, physical, and mental.

The other thing about body positivity is it kind of puts the onus on the person to do their own inner work, to try to cultivate some kind of love for their body, Harris said. Really, the onus is on culture and society to get with the program, let everybody be who they are.

Speaking from personal experience as a sorority member at UW, I have found this to be the hardest environment to be in with regard to keeping a positive body image.

While I have experienced the body image issues that every other human has, I have the privilege of never having seriously struggled with an eating disorder. Still, I have found it incredibly hard not to neglect my body.

I can feel the panic that goes through some of my closest girlfriends when they walk into our kitchen and are faced with the daunting task of choosing and eating a meal.

We still need to do a much better job as college women. It is long overdue that we give ourselves, and each other, a break when it comes to our bodies that do so much for us.

Reach writer Mary Murphy at opinion@dailyuw.com. Twitter: @marymurphy301

Like what youre reading? Support high-quality student journalism by donating here.

Read more:
OPINION: Give your body a break | Opinion | dailyuw.com - Dailyuw

Recommendation and review posted by Bethany Smith

Health and wellbeing: PCOS? Its time to spell out the facts Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. All SectionsHealth and wellbeing: PCOS? Its time to spell out the facts

Read more:
Health and wellbeing: PCOS? It's time to spell out the facts - The Sunday Post

Recommendation and review posted by Bethany Smith

Marijuana has never been more popular throughout the United States. According to several studies and research centers, an overwhelming number of Americans support legalization. With more and more states decriminalizing marijuana use, hemp production and the growth of the cannabis seeds industry are also on the rise.

As a result of this demand, the internet is now stacked with cannabis seed banks that ship globally. You will find thousands of these online seed banks with a quick Google search. They provide home growers with the seeds needed to grow cannabis strains, making many people consider growing their cannabis plants at home.

With this new and largely unregulated industry, vendors have a wide range in quality. For example, some may provide you with high-quality seeds, while others may distribute marijuana seeds that did not successfully germinate. However, not all of them are reputable seed banks.

To help you find trustworthy, high-quality marijuana seeds, we have compiled a list of the best online seed banks. Youll be able to easily order the cannabis seeds and start producing them in no time!

I Love Growing Marijuana sells premium marijuana seeds of so many different types. Whether you are a pro who has been at this for a while, or someone looking to try this for the first time, there are seeds with your name on them!

The site is also a great learning tool. If you dont know a lot about growing marijuana, this site is full of resources to get you started. Once you got a handle on the growing process, you can experiment with other types of strains until you are growing plants perfect for your needs.

Sometimes you dont know what kind of seeds you want, but you know what you need them to treat. Sometimes you dont know what kind of seeds you want, but you know what kind of climate you have for growing them. Thats where MSNL comes into play.

MSNL is a great site for buying seeds to treat a specific illness. For example, if you are suffering from post-traumatic stress disorder, you can buy seeds that are proven to help treat that disorder.

If you leave in a dry, arid climate, you can buy seeds that will grow and flourish in that climate. This is a great tool if you dont know what kind of seeds will grow well where you live. For research purposes, you cant beat this site.

You dont exactly always want people to know that you are growing marijuana. You also arent always in an area where it is easy to get marijuana seeds shipped to you. Thats where the Ministry of Cannabis comes in clutch. This service will ship to you no matter where you are in the world, and the packaging is discreet.

Although the site offers feminized and auto-flowering seeds, the site is really well-known for its CBD products. CBD products are great for reducing stress and anxiety as they help make you more mello.

If you arent sure what specific seeds you want, but you know what you want them to do, you can buy a packet of mixed seeds. For example, you can buy a packet of Indica seeds all of which can have different flavors and potencies. Its a great way to experiment with new seeds while having an idea of what the end product will be.

If you want high-quality weed seeds that grow quickly, look no further than Rocket Seeds. It is one of the top cannabis seed banks worldwide, offering feminized seeds, regular seeds, CBD seeds, and more.

They perform quality checks to ensure successful germination for weed seeds. However, no germination guarantee covers growing methods other than their recommended one.

Rocket Seeds offers international deliveries and will even ship to the USA. They accept various payment methods, including all major credit cards, cash, money transfers, Bitcoin, PayPal, and more.

Beaver Seed is a great spot to buy marijuana seeds online. It is a Canadian-based seed bank that carries feminized, auto-flowering, regular, and high CBD seeds all for a reasonable price. The seeds and strains have high germination rates, growing into flourishing marijuana plants that eventually produce flowers.

This company has a high level of production standards. The weed seeds are always inspected and carefully selected before being shipped.

Furthermore, Beaver Seeds regularly offers discounts and promotions, even on new marijuana strains.

Since 2007, Herbies Head Shop has been known as one of the best seed banks for cannabis enthusiasts. They offer a unique collection of seeds such as photoperiod seeds, high THC or CBD seeds, and fast flowering options.

Even with over 3,000 seeds for sale, all products are brand-only cannabis seeds that guarantee a harvest of the most potent marijuana. Plus, Herbies team of online consultants will gladly help you pick a seed bank or a specific strain if you need assistance.

Herbies also offers stealth shipping for maximum confidentiality. With this option, the marijuana seeds are removed from the original packaging, placed into Ziploc bags, and disguised as random items.

My Fast Buds is an excellent cannabis seed bank that has won several awards internationally. They specialize in auto-flowering cannabis plants, the ideal option for beginner growers.

All strain genetics are tailored for fast growth and have an impressive 98% germination guarantee. If a seed doesnt germinate, Fast Buds will send you free cannabis seeds as a replacement.

Fast Buds carries a total of 45 auto-flowering strains, including their best-sellers Gelato, Strawberry Pie, and Zkittlez.

Sonoma Seeds is a West Coast-based, premium cannabis seed supplier that distributes strains worldwide.

This online seed bank features a large seed selection from over 500 strains, including Indica seeds, hybrid seeds, Sativa seeds, CBD seeds, and more. They handpick everything and only offer high-quality marijuana seeds with an 80% germination rate.

Sonoma Seeds ships to customers worldwide and even offers free shipping for orders over $300. The site will accept various payment methods, including money transfers, e-transfers, cash, bitcoin, and major credit cards.

Seedsman started to sell cannabis seeds back in 2003. This company is a leader in the industry and remains at the forefront of cannabis innovation. For example, Seedsman was one of the first seed banks to commercialize auto-flowering and CBD genetics.

Its effortless to buy cannabis seeds online via the Seedsman website. They offer several categories of marijuana seeds such as feminized, auto-flowering, regular, high THC, high CBD, along with indoor and outdoor seeds.

All cannabis seed genetics are sourced from expert breeders worldwide, ensuring highly potent THC seeds and high-quality CBD cannabis seeds.

Seedsman also provides international shipping options, discreet packaging, updated order tracking, and various payment options. Additionally, the website has an informative blog where you can catch up on cannabis news, insights, and more.

If you are looking to buy seeds at a reasonable price then Sensible Seeds is your one-stop-shop. The site has a ridiculous amount of seeds for you to check out and purchase.

If you are looking for feminized, auto-flowering, medical-grade, or a high-CBD strain, there are seeds here with your name on them. Explore the hundreds of choices to find the ones that work best for you and at a price that wont break the bank!

As with other flowering plants, cannabis creates seeds that contain the genetic information needed for growth and reproduction.

Once the seed successfully germinates (or once the root has broken through the seed), it is ready to grow into a mature plant.

Cannabis seeds are around the size of a peppercorn, and most have light brown specks throughout the body.

Some cannabis on the market today does not contain seeds. In the middle of the 20th Century, growers realized that culling male plants once they displayed sex traits would only result in the crop containing unfertilized female plants.

It yielded cannabis plants with higher amounts of THC, plus they dont require the removal of seeds before smoking. These widespread advancements in cultivation practices have enabled seedless cannabis to be mass-produced and distributed throughout the globe.

You can find Cannabis seeds in several forms regular, feminized, and auto-flowering seeds. Most marijuana home growers prefer to grow feminized seeds.

Feminized seeds have been bred only to produce female plants. This matters for cultivation purposes. Female plants exclusively produce smokable flowers.

Regular seeds do not have this option. They produce male and female seeds, meaning there is no way to predict whether the mature plant will be female.

In addition to feminized marijuana seeds and regular seeds, some growers also use auto-flowering seeds. These seeds have been carefully engineered to begin and finish the flowering process without needing to be induced by changes in light throughout the day.

Auto-flowering seeds tend to be easier to grow since they dont require as much light as regular or feminized seeds, ideal for short or indoor growing seasons.

The legality of marijuana will depend on your location. Marijuana seeds are considered a cannabis-based product, meaning if you live in a place where marijuana is legal, then the seeds are also legal and vice versa.

If you want to buy cannabis seeds in a state where its illegal, you will face some degree of risk. There is a gray area where you can purchase marijuana seeds from seed banks as a souvenir, but this strategy is still dicey.

If you live in a weed-legal state (one where home growing is allowed), you should have no issue buying cannabis seeds online from a seed bank.

You have a couple of options, whether buying cannabis seeds online or in person. Cannabis seeds are sold in retail locations and through online seed banks. If you live in a country or state where cannabis use and growing marijuana is legal, you should buy the seeds at local dispensaries.

Furthermore, there are various online seed banks on the market. Choosing cannabis seed banks keenly is vital to ensure your investment does not go wasted. Many seed banks do not provide a germination guarantee, which is a critical step and should be a top priority when buying marijuana seeds online. If the germination process fails, so will everything else.

It largely depends on the vendor and the quality of the product. The price for your cannabis seeds will vary based on a few factors, including:

A package of marijuana seeds (which typically contains around 10 seeds) may run you anywhere from $40 for lower quality seeds and up to $400 or $500 for high-quality cannabis seeds.

You can expect high-quality cannabis seeds from this list of the best online seed banks. These well-established brands will not waste your money on cannabis seeds that did not even germinate. Ultimately, the decision will come down to your specific preference. You can consider variables such as seed types, shipping times and costs, and whether the vendor offers multiple payment methods. Overall, you cant go wrong with these reputable seed banks.

Read this article:
10 Best Seed Banks 2022: Top Cannabis Seed Banks That Ship to USA - Washington City Paper

Recommendation and review posted by Bethany Smith

(March 2020)

It is predicted the development of a safe and effective vaccine to prevent COVID-19 will take 12 to 18 months, by which time hundreds of thousands to millions of people may have been infected. With a rapidly growing number of cases and deaths around the world, this emerging threat requires a nimble and targeted means of protection.

Could CRISPR be the next virus killer?

To address this global pandemic challenge, we are developing a genetic vaccine that can be used rapidly in healthy and patients to greatly reduce the coronavirus spreading. We developed a safe and effective CRISPR system to precisely target, cut and destroy COVID-19 virus and its genome, which stops coronavirus from infecting the human lung.

Weve shown that the CRISPR system can reduce 90% of coronavirus load in human cells. It can also protect humans against essentially 90% of all current and emerging coronaviruses. The project is ongoing, and we are working around the clock towards getting an actual product by combing our CRISPR method with an inhaler-based delivery device.

The project will likely to result in a potential therapeutics towards COVID-19, which can help slow down or eliminate the outbreak.

Relevant Publications or More Information

A preprint of the work (not yet peer reviewed)

Feature in WIRED magazine(March 18, 2020)

Collaborators:

Stanley Qi(Bioengineering)

David Lewis(Pediatrics-Immunology)

Jennifer Cochran(Bioengineering)

Drew Endy(Bioengineering)

Go here to see the original:
New genetic method of using CRISPR to eliminate COVID-19 virus genomes ...

Recommendation and review posted by Bethany Smith

Gado/Getty Images

CRISPR Therapeutics, which as its name suggests, is focused on using CRISPR-Cas9 gene editing to generate gene-based therapies for serious diseases, is expecting a busy year. And as reported in its first-quarter financials, as of March 31, it had $2.221 billion in cash, cash equivalents and marketable securities to drive its progress.

The company, along with collaboration partner Vertex Pharmaceuticals, expects to present updated data from its ongoing Phase III trials for CTX001 in transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). They had announced that more than 75 patients in both trials had been dosed last quarter. They have also initiated two new Phase III trials of the therapy in pediatric patients with TDT and SCD. They plan to submit global regulatory filings for CTX001 for those two indications later this year.

I am pleased with the ongoing momentum across our broad portfolio of innovative gene therapy candidates and anticipate important company milestones in 2022, stated Samarth Kulkarni, Ph.D., chief executive officer of CRISPR.

On February 2, CRISPR and ViaCyte dosed the first patient in a Phase I trial of VCTX210 for treatment of type 1 diabetes (T1D). VCTX210 is an allogeneic, gene-edited, stem cell-derived therapy designed to generate pancreatic cells that can evade recognition by the immune system. In theory, these replacement cells would allow patients to produce their own insulin.

We are excited to work with CRISPR Therapeutics and ViaCyte to carry out this historic, first-in-human transplant of gene-edited, stem cell-derived pancreatic cells for the treatment of diabetes designed to eliminate the need for immune suppression, said Dr. James Shapiro, M.D., Ph.D., Canada Research Chair, Director of the Islet Transplant Program at the University of Alberta, and a clinical investigator of the trial. If this approach is successful, it will be a transformative treatment for patients with all insulin-requiring forms of diabetes.

In addition to that trial, the company indicated in its quarterly report that based on progress with its in vivo techniques for liver gene editing using both viral and non-viral vectors, is expected to move multiple programs leveraging in vivo approaches into the clinic in the next 18 to 24 months.

CRISPR has also made inroads with its immuno-oncology programs. It is continuing to enroll and treat patients in the Phase III trial of CTX110, an allogeneic chimeric antigen receptor T cell (CAR-T) therapy targeting CD19+ B-cell malignancies. It expects to report additional data this year. And it also has ongoing Phase I trials for CTX-120, its wholly-owned allogeneic CAR-T therapy targeting B-cell maturation antigen for relapsed or refractory multiple myeloma, and CTX130, a CAR-T therapy targeting CD70 for solid tumors and certain hematologic malignancies. CRISPR Therapeutics expects to offer updates for both trials in the first half of this year.

Total collaboration revenue was $0.2 million for the first quarter of 2022 and 2021. For this quarter, R&D expenses were $118.2 million, up from $70.6 million in the same period last year. This was driven largely by its immuno-oncology programs and expenses associated with its new U.S. R&D headquarters. General and administrative (G&A) expenses were $28.0 for the first quarter, up from $24.5 million in the first quarter of 2021, driven by headcount-related expenses. Overall, it reported a net loss of $179.2 million for the first quarter.

Simply Wall St. conducted an analysis of CRISPR Therapeutics investors. It noted the company has a market capitalization of $3.7 billion, and usually a company this size would have a high percentage of institutional investors, which does seem to be the case with CRISPR. This suggests some credibility amongst professional investors. But we cant rely on that fact alone since institutions make bad investments sometimes, just like everyone does, they write.

Institutional investors own more than half the issued stock that is not owned by hedge funds. The largest shareholder is ARK Investment Management, with 12%; the second largest, also with 12% of common stock, is Nikko Asset Management Col, and third, Capital Research and Management Company owns about 5.3% of the company stock.

In terms of the shareholders, 50% of ownership is controlled by the top 25 shareholders, meaning that no single shareholder has a majority interest in the ownership. Insider ownership makes up about $54 million in shares at current prices, while individual public investors hold a 35% stake. While this size of ownership may not be enough to sway a policy decision in their favor, they can still make a collective impact on company policies, writes Simply Wall St.

Kulkarni concluded, saying, We believe we are well-positioned and well-capitalized to advance our pipeline and platform to develop transformative medicines for patients suffering from serious disease.

Read more from the original source:
Cash-Rich CRISPR Therapeutics Expects Year Filled with Milestones - BioSpace

Recommendation and review posted by Bethany Smith

The CRISPR-Cas9 Market Report Forcast to 2022-2028 offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining key insight into the market. The study includes porters five forces model, attractiveness analysis, and competitor position grid analysis.The study also contains information about the CRISPR-Cas9 industrys regulatory environment, which will assist you in making an informed decision. The paper goes through the important regulatory agencies, as well as the major rules and regulations that have been put on this industry in different parts of the world.

Get Updated Sample Report (Get Higher Priority for Corporate Email ID): https://www.worldwidemarketreports.com/sample/493454

Segmentation based on Key players

Editas Medicine CRISPR Therapeutics Horizon Discovery Sigma-Aldrich Genscript Sangamo Biosciences Lonza Group Integrated DNA Technologies New England Biolabs Origene Technologies Transposagen Biopharmaceuticals Thermo Fisher Scientific Caribou Biosciences Precision Biosciences Cellectis Intellia Therapeutics

Segmentation based on Type

Biotechnology Companies Pharmaceutical Companies Others

Segmentation based on Application

Genetic Engineering Gene Library Human Stem Cells Others

Request a PDF Brochure here: https://www.worldwidemarketreports.com/sample/493454

The study also includes a regional analysis that covers various regions and contributes to the CRISPR-Cas9 markets growth. It includes the competitive landscape, which comprises the leading players, as well as strategies for announcing collaborations, introducing new products, and collaborating to help the CRISPR-Cas9market expand between 2022 and 2028. Furthermore, the research analyst has used a variety of research approaches to gather data on current trends and industry advancements that will drive CRISPR-Cas9market growth throughout the projection period.

Summary

Our research analysts will assist you in obtaining customized information for your report, which can be tailored to a particular region, application, or statistical detail. Furthermore, we are always happy to cooperate with a study that is triangulated with your own data in order to make the CRISPR-Cas9market research more thorough in your eyes.

An Overview of the Impact of COVID-19 on this Market:

COVID-19 appearance has brought the entire globe to a halt. We recognize that the current health crisis has had a significant impact on businesses in a variety of sectors. Governments and businesses are rallying to tackle this potentially dangerous disease. Some industries are doing well, while others are failing. During COVID-19 pandemics, we are working hard to keep your company afloat and growing. We will provide you with impact analysis of the coronavirus outbreak across industries, based on our knowledge and expertise, to assist you in planning for the future.

To learn more about the impact of Covid-19 in this report, go to: https://www.worldwidemarketreports.com/covidimpact/493454

Competitiveness Quadrants

A Competitive Quadrant, a patented methodology for analyzing and evaluating organizations positions based on their Industry Position and Market Performance scores, is also included in the report. The tool categorizes the participants into four groups depending on a number of factors. Financial performance from the last few years, growth strategies, innovation techniques, new product launches, investments, CRISPR-Cas9market share growth, and other factors are all taken into consideration.

What are the advantages of purchasing this report?

FAQ:

Buy this Research report Complete With Tables, Figures, Charts, and More:https://www.worldwidemarketreports.com/buy/493454

Contact Us :

Mr. ShahWorldwide Market Reports,Tel: U.S. +1-415-871-0703U.K. +44-203-289-4040Japan +81-50-5539-1737Email: [emailprotected]Website: https://www.worldwidemarketreports.com/

Read more:
COVID -19 Impact Study: CRISPR-Cas9 Market Is Expected to Witness an Incredible Growth by 2028: Editas Medicine, CRISPR Therapeutics, Horizon...

Recommendation and review posted by Bethany Smith

He Jiankui, known to his international colleagues as JK, is a scientist who was well-respected in the American gene editing community, but pushed the boundaries by gene-editing on an embryo.PHOTO ILLUSTRATION: BRYAN GEE/THE GLOBE AND MAIL. SOURCE: AP Photo/Kin Cheung

Samira Kiani is a professor of genetic engineering at the University of Pittsburgh. She is the co-producer of Make People Better, which premiered at this week at Hot Docs. The views presented are those of the author and do not necessarily represent the views of the University of Pittsburgh. This essay was co-written with journalist Brian Barth.

In October, 2018, I was invited to a secret meeting in Guangzhou, China. I was there because of my work as a genetic scientist who uses the CRISPR technology to cut and splice DNA, an approach to genetic engineering that has come to the forefront over the past decade. I dont think its an overstatement to say that CRISPR, a precise and efficient tool that allows us to edit genes, is on the verge of altering the course of human history to an extent far greater than the recent disruptions catalyzed by internet technology. If you think digital surveillance tools are frightening in the hands of autocracy, consider the power to bend the human genome to ones will. CRISPR provides that power. To use another analogy, the ability to edit genes with surgical precision is a scientific discovery on par with nuclear fission while there may be beneficial applications, it is by nature seductive to our darkest impulses.

Because of CRISPRs unknown risks, its use has been limited to certain applications by longstanding consensus within the scientific community, and to a lesser extent by regulatory agencies. Weve experimented extensively in petri dishes and increasingly on live animals. Theres been limited experimentation on human embryos in the lab, but a firm line has been drawn: Edited embryos are not to be implanted in womens bodies.

The man I met with in the lobby of the Westin hotel in Guangzhou had crossed that line. His name is He Jiankui, and his story has since been told. This is the first time Im telling my version.

I was in Guangzhou, a hotbed of biotech research, making a film that looks at all sides of this god-like power. Im as interested in the ethical implications of my work as I am in the technology itself, and have long worked at the intersections of science, art and society. Dr. He, known to his international colleagues as JK, was seeking a messenger, someone who could translate his work to the world in a way that would elicit sympathy, rather than horror. He seemed to think this was his chance.

Needless to say, our meeting changed the course of the film. It also changed the course of his life, and not for the better he spent the next three years in prison after being convicted of illegal medical practice. He was released in April.

For me, the meeting in Guangzhou was a turning point. It clarified something Id sensed internally for years: The dark sides of technological advancement have roots in the culture of science. Ive been part of that culture my entire life my childhood in Iran as the daughter of veterinary scientists; the medical school in Tehran my family pushed me to attend; my postdoctoral work at Massachusetts Institute of Technology with hard-charging CRISPR pioneers; my marriage to a stem cell researcher. If youre not at the top of your class, publishing in the most prestigious journals, getting the biggest grants and making the biggest breakthroughs, then youre a nobody. Its a culture of more, better, faster; of accomplishment at any cost, whether personal or societal. If someone gets hurt, if theres collateral damage so what? Its inevitable in the brutal contact sport of science.

Ive come to have a measure of empathy for JK because I understand that his choices are a product of the culture of the scientific community, a community that ultimately threw him under the bus rather than face its complicity. My meeting in Guangzhou put me on a path to change that culture. It hasnt been easy.

When JK invited our film crew to the off-the-record meeting, he did not give us the full story. He said he would soon implant edited embryos into human subjects and asked if this was something wed like to document on film. Turned out he had already done the deed twins given the pseudonyms Lula and Nana had been born just before we met (this was unearthed shortly after our meeting by the journalist Antonio Regalado, a subject in the documentary who wed invited to join us at the hotel). When the news broke, the Western scientific community feigned disgust JK was a rogue, conveniently located in a distant autocracy, who had carried out this horrible project in secret. That narrative could not have been further from the truth.

While I did not personally know him, plenty of scientists in the West did, and hed openly shared what he was up to with some of them. JK, was a young, highly ambitious scientist. Hed been educated at Stanford and was well-respected in the American gene editing community. He aimed high in his career, as in Nobel laureate-level. Nuclear fission-scale discoveries are what win Nobel Prizes never mind what happens with the technology later. He knew that the birth of gene edited human babies would shock the world; it was a calculated risk, in which he hoped the shock would subside into acceptance. He imagined that history would eventually celebrate him as the first.

JKs colleagues did not call him out before the news leaked because what he was doing, while considered taboo by society at large, is seen as an inevitability among CRISPR scientists. The fact that we edit human embryos at all should make it obvious that implanting those embryos is the anticipated next step. It is less scientific knowledge holding back the industry than social licence and regulatory environment.

The culture of science was pushing JK forward. Like me and many of my colleagues, he wanted to change the world for the better, and he understood that this did not happen by colouring within the lines. It requires pushing boundaries the question is which ones you push. The answers, I believe, should come not from a sense of competition with the guy next to you on the lab bench, but from the broadest possible cross-section of human communities. The culture of science is like a vacuum perhaps because we know the general public often does not understand what we do, we dont feel like were obligated to explain ourselves, much less to elicit input from beyond our silo walls. Integrating input from diverse perspectives is, for many scientists, a foreign concept, something that would divert from ones goals and slow the process of discovery. Theres truth in that, but I think it would redirect scientific goals to be more in alignment with human needs. Moving slower and not breaking things has its upsides.

Pushing boundaries is essential to human achievement, but the harder the push, the greater the responsibility. At a minimum, you need consent from those involved, which is why editing the DNA of a human embryo is an ethical abyss: Unborn children cannot give consent. In any matter related to public health, there must also be some form of collective consensus about the risks involved and when it comes to the integrity of the human gene pool, the bar couldnt be higher.

In JKs case, he deluded himself into thinking he had consensus to proceed with his experiment. During our meeting, he showed me the results of public opinion surveys indicating relatively strong support for gene editing in China. He had also obtained ethics approval from the medical institution involved in the project (Chinese authorities later claimed the approval was fraudulent). He was also banking on support for the specifics of the experiment to make Lulu and Nana genetically immune to HIV. While theres an obvious selling point for the public there, we have other tried and true methods at our disposal for controlling the spread of HIV. What the layperson would not realize, however, is that his choice in which genes to work with was also a matter of scientific expediency, as the mutation associated with HIV resistance, known as CCR5-delta 32, has been intensely studied and thus represents a low barrier to entry for someone wanting to feel reasonably confident that nothing will go awry when they start editing embryos.

Nonetheless, the experiment did not go as planned. We inherit a pair of each gene that comprises our genome (one from our mother and one from our father), but one of the twins embryos came out half-edited, meaning the intended change happened only on the copy from one parent. Second, he was unable to confirm that the genetic changes made in the embryos resulted in immunity to HIV. The fact that JK chose to implant the embryos anyway he claimed this was in part because the parents urged him to is a core ethical lapse largely overlooked in press reports.

JK had tacit support from the Chinese government for his work, but when the situation became suddenly scandalous in late 2018, they turned on him, just like his colleagues. Even if theyd stood by him, I dont believe the approval of a single jurisdiction has any relevance when it comes our shared genome, which transcends national borders. In my mind, to alter genes that will be passed down from generation to generation is a sacred act. Placing responsibility for it in the hands of regulatory agencies is to deny the full power and meaning of it. If we choose this path through a truly responsible process a big if there would be no need for the scientists involved to feel like they need to hide what theyre doing. They would be vaunted in the temples of the world.

Still from the film Make People Better, directed by Cody Sheehy and produced by author Samira Kiani shows the gene edited twin girls, nicknamed Lulu and Nana, who were born at an undisclosed hospital in China.COURTESY HOTDOCS AND Getty Images

I am by no means against gene editing it is my passion and livelihood. It has potential to cure our most intractable diseases and possibly address some of our most pressing environmental issues. Part of the promise of CRISPR is safety: Because it is so precise, the risk of unintended negative outcomes is much smaller and easier to mitigate than the previous generation of genetic engineering tools. We have conclusive evidence regarding safety for many applications of CRISPR technology. But this is not universally the case.

My own research involves somatic gene editing, a therapeutic application of CRISPR administered by injection to consenting subjects. JK, and a small number of other scientists, have experimented with germline editing, in which changes are made to the DNA of an embryo. Theres a huge difference: With somatic gene editing, the altered genetic traits cannot be passed to future generations, but with germline they can, permanently releasing those new traits into the gene pool. This makes germline far riskier.

We simply do not know the biological implications of human germline editing, and cant fully know them without waiting 80 years to see how an embryos altered genome plays out over the course of a lifetime. The culture of science is not equipped with that sort of patience. The social and political implications of gene editing are also huge unknowns, and unfortunately theres been scant debate among policy makers and the general public. Within the small, insular world of CRISPR researchers, it is assumed that work similar to JKs is under way, most likely in privately funded labs, or in countries where the idea of engineering humans for morally questionable reasons think designer babies and superhuman soldiers could be viewed not as taboo, but as politically and economically desirable.

At this point, we have little ability to anticipate the unintended negative consequences that might result from germline editing, but such uncertainties have not stopped the forces of hubris in the past. Nor have they stopped the forces of capital. I expect that human genetic engineering, both therapeutic and vanity applications, will become an unfathomably profitable industry in the coming decades. I am open to the possibility that germline editing could be ethically applied in narrowly defined arenas of public health. But the determination of where to draw the lines should not be left up to venture capitalists and self-centred founders, as it was to a large extent with the IT industry. They are already salivating.

In many ways, the present state of gene editing technologies resembles that of internet technologies 25 years ago on the cusp of changing the world, but still obscured behind closed doors. Many of us now wish that wed better understood the implications of those technologiesthen. If theres any hope of the biotech industry of the future having a moral, equitable and inclusive basis, the rules of engagement need to be determined now.

How do we catalyze a meaningful public debate before its too late? First, the public needs to better understand how theses technologies work and what the implications are. I believe communicating that should be part of the job description for all scientists. Second, scientists need to approach their work with a more holistic lens. The scientific method is by nature reductive, but we need not be reductive in deciding how to apply it and which paths of inquiry to pursue.

I have profound respect for the intellect and integrity of my colleagues. But I see a direct link between a difficulty with introspection or perhaps unwillingness, Im not sure which and the ethical shortcomings of my community. I often wonder how our discoveries, and the world that they foster, would look if EQ was valued as much as IQ. Im not saying individual scientists lack emotional intelligence in their personal lives, but on a collective level we do. Its evident in how we practise our work and in our relationship with society at large. Pushing ones way to the front of the line is not a sign of high EQ. But thats the culture of science. Ignoring what other people feel because it does not align with our needs or desires does not make for good relationships. But it makes for a successful scientist.

I dont have all the answers. But Im trying to transform the tiny domains where I have influence. Im developing a virtual museum to help educate the public about gene editing, highlighting both the benefits and the dangers. Im producing films and theatre that ask the hard questions about boundary-pushing innovations not just genetic engineering, but others on the verge of altering human history, such as AI and brain-machine interfaces in entertaining and unexpected ways. I am also one of the co-creators of Our Future Life, a global storytelling initiative aimed at breaking down barriers to dialogue around the biggest questions facing humanity. The common thread in all these is to engage the public imagination and encourage deep reflection. Perhaps most importantly, I work on a daily basis to instill these perspectives in my students. Believe me, it is an uphill battle.

When I was invited recently to give a guest lecture for a colleagues class on epigenetics, I decided to use the opportunity to facilitate a discussion about who the students are as scientists, rather than giving a dry talk on theory and technique. A month later, the professor whod invited me informed that Id received horrible reviews in the class evaluations. My presentation was not pertinent to the material, one student wrote. I couldnt disagree more.

Keep your Opinions sharp and informed. Get the Opinion newsletter. Sign up today.

See the rest here:
Opinion: Human genetic engineering is coming. We must discuss the social and political implications now - The Globe and Mail

Recommendation and review posted by Bethany Smith

The following discussion and analysis of our financial condition and results ofoperations should be read in conjunction with (i) our unaudited condensedconsolidated financial statements and related notes appearing elsewhere in thisQuarterly Report on Form 10-Q and (ii) our audited consolidated financialstatements and related notes and management's discussion and analysis offinancial condition and results of operations included in our Annual Report onForm 10-K for the year ended December 31, 2021 filed with the Securities andExchange Commission, or the SEC, on February 15, 2022. Some of the informationcontained in this discussion and analysis or set forth elsewhere in thisQuarterly Report on Form 10-Q, including information with respect to our plansand strategy for our business and impact and potential impacts on our business,includes forward-looking statements that involve risks and uncertainties. As aresult of many factors, including, without limitation, those factors set forthin the "Risk Factors" section of our Annual Report on Form 10-K for the yearended December 31, 2021 and the "Risk Factors" section of subsequent QuarterlyReports on Form 10-Q, our actual results or timing of certain events coulddiffer materially from the results or timing described in, or implied by, theseforward-looking statements.

Special Note About Coronavirus (COVID-19)

Overview

We and Vertex have also initiated two additional Phase 3 clinical trials ofCTX001 in pediatric patients with TDT and SCD.

Immuno-Oncology

In addition, we are developing our own portfolio of CAR-T cell productcandidates based on our gene-editing technology.

In the fourth quarter of 2021, we released updated clinical data from theongoing CARBON trial for 26 patients treated with CTX110 who had reached atleast 28 days of follow-up.

Regenerative Medicine

In Vivo

Partnerships

Financial Overview

Revenue Recognition

Research and Development Expenses

employee-related expenses, including salaries, benefits and equity-basedcompensation expense;

costs of services performed by third parties that conduct research anddevelopment and preclinical and clinical activities on our behalf;

costs of purchasing lab supplies and non-capital equipment used in ourpreclinical activities and in manufacturing preclinical and clinical studymaterials;

facility costs, including rent, depreciation and maintenance expenses; and

fees and other payments related to acquiring and maintaining licenses under ourthird-party licensing agreements.

successful completion of preclinical studies and IND-enabling studies;

successful enrollment in, and completion of, clinical trials;

receipt of marketing approvals from applicable regulatory authorities;

establishing commercial manufacturing capabilities or making arrangements withthird-party manufacturers;

obtaining and maintaining patent and trade secret protection and non-patentexclusivity;

launching commercial sales of the product, if and when approved, whether aloneor in collaboration with others;

acceptance of the product, if and when approved, by patients, the medicalcommunity and third-party payors;

effectively competing with other therapies and treatment options;

a continued acceptable safety profile following approval;

enforcing and defending intellectual property and proprietary rights and claims;and

achieving desirable medicinal properties for the intended indications.

Except for activities we perform in connection with our collaborations withVertex and ViaCyte, as well as in connection with the Bayer Transaction, we donot track research and development costs on a program-by-program basis.

General and Administrative Expenses

Collaboration Expense, Net

Collaboration expense, net, consists of collaboration costs under ourcollaboration with Vertex.

Other Income (Expense), Net

Other income (expense), net consists primarily of interest income earned oninvestments.

Results of Operations

Comparison of three months ended March 31, 2022 and 2021 (in thousands):

3,504

Research and Development Expenses

$8.8 million of increased facility-related expenses, primarily related to ournew U.S. research and development headquarters;

$3.7 million of increased license fees; and

$2.9 million of increased consulting and professional services costs.

General and Administrative Expenses

$2.2 million of increased employee compensation, primarily due to increasedstock-based compensation expense of $1.9 million; and

$1.3 million of increased consulting and professional services costs.

Collaboration Expense, Net

$6.5 million of increased pre-commercial expenses associated with ourcollaboration with Vertex;

$5.3 million of increased manufacturing costs; offset by

$1.3 million of decreased other costs.

Other Income, Net

Liquidity and Capital Resources

Outlook

Cash Flows

The following table provides information regarding our cash flows for each ofthe periods below (in thousands):

Period to Period

Net cash used in operating activities $ (135,239 ) $ (100,663 ) $ (34,576 )Net cash used in investing activities

Investing Activities

Financing Activities

Critical Accounting Policies and Significant Judgments and Estimates

Recent Accounting Pronouncements

Edgar Online, source Glimpses

More here:
CRISPR THERAPEUTICS AG Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics (NASDAQ:CRSP Get Rating) had its price objective decreased by investment analysts at Barclays from $107.00 to $99.00 in a report issued on Tuesday, The Fly reports. Barclayss price target would indicate a potential upside of 129.01% from the companys current price.

Other research analysts have also recently issued research reports about the stock. Credit Suisse Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, April 28th. They set a neutral rating and a $78.00 price target on the stock. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $171.00 to $168.00 in a report on Tuesday. Truist Financial restated a buy rating and issued a $220.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, February 16th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $179.00 to $87.00 and set a neutral rating on the stock in a report on Thursday, February 17th. Finally, Stifel Nicolaus cut their price target on shares of CRISPR Therapeutics to $64.00 in a research note on Wednesday, February 16th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has an average rating of Buy and a consensus target price of $124.64.

Shares of CRSP opened at $43.23 on Tuesday. CRISPR Therapeutics has a 52-week low of $43.05 and a 52-week high of $169.76. The firms fifty day moving average is $59.95 and its two-hundred day moving average is $69.03. The stock has a market cap of $3.35 billion, a PE ratio of 9.78 and a beta of 2.05.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $289,982,000. Nikko Asset Management Americas Inc. boosted its holdings in shares of CRISPR Therapeutics by 7.0% in the first quarter. Nikko Asset Management Americas Inc. now owns 4,619,747 shares of the companys stock valued at $291,044,000 after acquiring an additional 300,276 shares during the period. Loomis Sayles & Co. L P boosted its holdings in shares of CRISPR Therapeutics by 42.1% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,316,123 shares of the companys stock valued at $99,736,000 after acquiring an additional 390,209 shares during the period. BlackRock Inc. boosted its holdings in shares of CRISPR Therapeutics by 12.6% in the fourth quarter. BlackRock Inc. now owns 1,271,528 shares of the companys stock valued at $96,358,000 after acquiring an additional 142,244 shares during the period. Finally, Bellevue Group AG boosted its holdings in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bellevue Group AG now owns 974,684 shares of the companys stock valued at $109,096,000 after acquiring an additional 7,800 shares during the period. 56.12% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $99.00 at Barclays - Defense World

Recommendation and review posted by Bethany Smith

This article was originally published here

Yonsei Med J. 2022 May;63(5):480-489. doi: 10.3349/ymj.2022.63.5.480.

ABSTRACT

PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen of coronavirus disease 2019. Diagnostic methods based on the clustered regularly interspaced short palindromic repeats (CRISPR) have been developed to detect SARS-CoV-2 rapidly. Therefore, a systematic review and meta-analysis were performed to assess the diagnostic accuracy of CRISPR for detecting SARS-CoV-2 infection.

MATERIALS AND METHODS: Studies published before August 2021 were retrieved from four databases, using the keywords SARS-CoV-2 and CRISPR. Data were collected from these publications, and the sensitivity, specificity, negative likelihood ratio (NLR), positive likelihood ratio (PLR), and diagnostic odds ratio (DOR) were calculated. The summary receiver operating characteristic curve was plotted for analysis with MetaDiSc 1.4. The Stata 15.0 software was used to draw Deeks funnel plots to evaluate publication bias.

RESULTS: We performed a pooled analysis of 38 independent studies shown in 30 publications. The reference standard was reverse transcription-quantitative PCR. The results indicated that the sensitivity of CRISPR-based methods for diagnosis was 0.94 (95% CI 0.93-0.95), the specificity was 0.98 (95% CI 0.97-0.99), the PLR was 34.03 (95% CI 20.81-55.66), the NLR was 0.08 (95% CI 0.06-0.10), and the DOR was 575.74 (95% CI 382.36-866.95). The area under the curve was 0.9894.

CONCLUSION: Studies indicate that a diagnostic method based on CRISPR has high sensitivity and specificity. Therefore, this would be a potential diagnostic tool to improve the accuracy of SARS-CoV-2 detection.

PMID:35512751 | DOI:10.3349/ymj.2022.63.5.480

Link:
Evaluation of CRISPR-Based Assays for Rapid Detection of SARS-CoV-2: A Systematic Review and Meta-Analysis - DocWire News

Recommendation and review posted by Bethany Smith

Since the academic discovery of gene editing, farmers, researchers and all of agriculture have heard many promises about its potential. The trouble is, theres all this excitement without taking a realistic look at what is needed to apply the technology in a way that it is in line with commercial needs.

Were at a point that we need to figure out these challenges or CRISPR wont work in the real world.

Next to the obvious regulatory and licensing hurdles, these challenges include considerable technical obstacles which still need to be overcome.

At Hudson River Biotechnology, weve been working on a CRISPR workflow for four years. We gave our workflow the acronym TiGER. One of the biggest hurdles we worked through was finding a way to obtain a homogenous, edited plant within a commercially attractive timeline.

This differs per crop, but in all cases meant stepping away from the use of transgenes, which is the primary academic way of applying CRISPR. Two great bonuses here are that our method is more controllable and therefore much more efficient and that without transgenes it can be applied in a much wider range of crops.

Whatever editing approach you work with, it goes hand in hand with the challenge of regenerating edited cells into a plant. Besides stepping away from transgenes, weve learned that the key to considerably reduce the time to market lies in single-cell regeneration.

Single-cell regeneration means that after editing, individual protoplasts are regenerated into a whole plant. The benefit of this is that no additional measures have to be taken to guarantuee genetic stability. In other words, we can yield a transgene-free, genetically homogenous plant in one generation. Weve adopted an effective, standardized single-cell regeneration approach and are making great strides with recalcitrant species by using smart delivery molecules, regeneration boosters and advanced materials adopted from the pharma world.

Cas9, while it made many headlines, is associated with a very expensive license. We needed to find something with high efficacy but a more affordable cost structure, which eventually brought us to the MAD7 protein. While there was less technical know-how for this protein, such as guide-design rules, and it is not commercially available, we tackled this by developing our own prorietery software and producing high-grade MAD7 in house. Thanks to this, we have been able to obtain very high editing effiencies and have managed precise gene editing, while using a protein that is commercially attractive for our clients.

Still, strides need to be made to harnass CRISPRs full potential. We still need to continue advancing the science behind CRISPR technologies and need to work diligently to inform consumers and politicians about what gene editing is. Its not transgenic, and we need to be clear about that.

From a communications perspective, we need to be talking with people outside of agriculture more. I mentioned regulatory hurdles as one of the challenges to using CRISPR, and if we dont explain science to the public, it could become an insurmountable challenge. We cant let gene editing go down the same public perception route that GMOs did we need this technology too much.

From a technical perspective, we need to spend time working with more crops and more genes. As you can imagine, we know a lot more about some crops staples like corn, soybeans, etc. than others, and its the same for their DNA. If we can do more research, well better understand how genes work together and how to impact important traits such as disease and insect resistance.

We also need to enhance our CRISPR capabilities to do precise gene-editing and target complex traits. Theoretically, all positions in the genome can be customized. In practice however, some genomic sites are poorly edited and repair is rarely precise in plants.

We continuously innovate to make precise editing of any position in the genome a reality. We also want to do this simultaneously at many different sites (multiplexing). This, in combination with more insight in how regulatory elements control (tissue specific) gene expression and how multiple genes conver complex traits, will allow us to truly harvest the full potential of CRIPSR. Transcending it from the blunt on-off switch that it is now, to a volume regulator that allows us to tune to any trait required and meet future crop challenges in this changing world.

Read the original post here

See original here:
Viewpoint: What are the most serious hurdles blocking mass adoption of gene editing in agriculture? - Genetic Literacy Project

Recommendation and review posted by Bethany Smith